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ABSTRACT
Mollicutes (mycoplasmas) are pathogenic in a wide range of mammals (including
humans), reptiles, fish, arthropods, and plants. Of the medically important mollicutes,
Mycoplasma gallisepticum is of particular relevance to avian agriculture and veterinary science,
causing chronic respiratory disease in poultry and turkey. Using two-dimensional electrophoresis
based quantitative expression proteomics, the current study investigated the molecular
mechanisms behind the phenotypic variability between a M. gallisepticum vaccine strain (6/85)
and a competitive, virulent field strain (K5234), two strains which were indistinguishable using
commonly accepted genetic methods of identification. Twenty-nine proteins showed a
significant variation in abundance (fold change > 1.5, p-value < 0.01). Among others, the levels
of putative virulence determinants were increased in the virulent K5234, while the levels of
several proteins involved with pyruvate metabolism were decreased. It is hoped that the data
generated will further the understanding of M. gallisepticum virulence determinants and
mechanisms of infection, and that this may contribute to the optimization of diagnostic
methodologies and control strategies.
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CHAPTER 1
INTRODUCTION

Mollicutes and Mycoplasma gallisepticum
Mycoplasmas (specifically Mycoplasma mycoides) were first isolated by Nocard and
Roux in 1898 (Waites and Talkington, 2004). The designation „mycoplasma‟ (mykes, fungi;
plasma, plasma formed) arose in the 1950‟s and described the organism‟s fungus-like growth, a
phenotype not actually observed in mycoplasmas other than M. mycoides. Since then
mycoplasmas have been grouped together in class Mollicutes (mollis, soft; cutis, skin - trivial
name, mollicutes or mycoplasmas), which consists of 4 orders, 8 genera, and over 200 species
(Johansson and Pettersson, 2002). 16S rRNA phylogenetic data suggest that mollicutes branched
off from low GC gram-positive bacteria roughly 600 million years ago (Fig. 1, p. 14), having
evolved since then by reductive (or degenerative) evolution, whereby they lost their cell walls
and many biosynthetic capabilities (Maniloff, 2002; Razin et al., 1998). To date, over 30
mollicutes have been completely sequenced, with genomes ranging in size from 580 to 1,359 kb
(Fig. 2, p. 15; Table 1, p. 16) (Barre et al., 2004). Because of their minute genomes, mollicutes
are the subject of intense research efforts aimed at defining the minimal gene compliment
required for life, and scientists such as J. Craig Venter are interested in using this data to
synthesize life in vitro (Glass et al., 2006).
Mollicutes are highly pleomorphic, exhibiting spherical (0.3 – 0.8µm in diameter), pear
shaped, flask shaped, and filamentous cell morphologies. Colonies are typically fried egg shaped
(Razin et al., 1998). Structurally, “Mollicutes are characterized by the complete lack of a cell
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wall and the presence of an internal cytoskeleton” (Wolf et al., 2004). Cell growth is unaffected
by cell wall synthesis-inhibiting antibiotics, and chemical analysis confirms the absence of
peptidoglycan, muramic acid, and diaminopimelic acid in mollicutes (Madigan et al., 2006).
Genetic studies show that mollicutes do not have the genes needed for the biosynthesis of these
cell wall components (Waites and Talkington, 2004).
Mollicutes are not as sensitive to osmotic shock as are typical protoplasts. This is due to
the presence of sterols, which are rigid and planar, in their cell membranes (unique among
bacteria). Some mollicutes possess lipoglycans which add to the stabilization of their membranes
(Madigan et al., 2006). The plasma membranes are also supported by an internal cytoskeleton
that is involved in modulating cell shape, cell division, localization of adhesins, and motility
(Balish and Krause, 2002; Razin et al., 1998).
While some mollicutes are strictly respiratory, most are facultative anaerobes (Madigan
et al., 2006). Glucose is metabolized by glycolysis or an incomplete pentose phosphate shunt.
Most non-fermentative and some fermentative mollicutes possess an arginine dehydrolysis
pathway. It is thought that substrate level phosphorylation during these catabolic pathways
accounts for most of the ATP production in mollicutes. Mollicutes lack TCA cycles, have
truncated electron transport chains (flavin terminated, no quinones or cytochromes), and are
incapable of oxidative phosphorylation (Pollock et al., 1997; Razin et al., 1998). Anabolism in
mollicutes relies heavily on the uptake of many biosynthetic precursors, including amino acids,
purines, pyrimidines, and cholesterols (Madigan, 2006). As Shmuel Razin states, “metabolic
activities appear to be associated primarily with energy production rather than providing
substrate for biosynthetic pathways” (Razin et al., 1998).
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Mollicutes have never been isolated as free-living entities in nature. Their limited
biosynthetic capabilities obligate them to symbiotic, commensal, or parasitic lifestyles. Parasitic
mollicutes are pathogenic in a wide range of mammals, reptiles, fish, arthropods, and plants
(Table 1, p. 16). Animal mycoplasmas colonize the epithelial cells of mucosal surfaces, such as
respiratory and urogenital tracts, alimentary canals, mammary glands, and joints. In humans,
mycoplasmas are the primary agents of urethritis and respiratory diseases, and two strains have
been implicated as cofactors in HIV infections (Barre et al., 2004; Razin et al., 1998).
Despite their medical relevance, little is known about the pathogenicity of mollicutes.
Infections are typically chronic, as mollicutes are able to subvert host immune responses by
cellular invasion, survival within phagocytic and non-phagocytic cells, and the generation of
phenotypic variants (Rottom, 2003). Potent toxins have not been identified, but mechanisms of
pathogenicity may include competition for biosynthetic precursors, damage induced by
cytadherence, damage induced by fusion, oxidative damage due to mildly toxic metabolic
byproducts such as hydrogen peroxide and superoxide radicals, cytopathic effects of hydrolytic
enzymes, and indirect damage resulting from the host‟s inflammatory and cellular responses
(Bradbury, 2005). Antimicrobial therapies have been only partially successful (Razin et al.,
1998).
Of the medically important mollicutes, M. gallisepticum is of particular relevance to
avian agriculture and veterinary science, contributing to chronic respiratory disease in poultry
and turkeys. Mycoplasma gallisepticum is one of the motile and predominately flask shaped
mollicutes (Fig. 3, p.17). The flask shape is conferred by a terminal tip organelle, which is
involved in attachment, motility, and cell division. The organism spreads through flocks laterally
by aerosol exposure and vertically by egg transmission and then colonizes respiratory tracts via
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attachment epithelial tissue (Papazisi et al., 2003). Mycoplasma gallisepticum has also been
isolated from the reproductive organs, brains, eyes, and joints of several avian species.
Dissemination within the host is thought to be aided by the organism‟s ability to adhere to,
penetrate, and survive within the host‟s red blood cells. Complications (decreased egg production
and increased vaccination and medication cost) caused by M. gallisepticum infections have a
severe negative economic impact on both the poultry and turkey industries (Papazisi et al.,
2003). Despite a worldwide impact, mechanisms of M. gallisepticum pathogenicity are not well
understood. Outbreaks are difficult to control, often necessitating eradication of diseased
populations (Papazisi et al., 2003).
Currently, there are three commercial M. gallisepticum live attenuated vaccine (LAV)
strains available in the United States: F-strain, ts-11, and 6/85. Strain 6/85 does not persist well
in birds but has low virulence and low potential for transmission from vaccinated to nonvaccinated chickens (Evans and Hafez, 1992). In 2002, a report was published that described a
6/85-like strain found within and near a flock of chickens that had been vaccinated with 6/85
(Throne-Steinlage et al., 2003). Increased mortality and sinus swelling were observed in both
vaccinated and unvaccinated birds. Tracheal cultures yielded a strain that was indistinguishable
from 6/85 by random amplified polymorphic DNA (RAPD) and gene-targeted sequencing (GTS)
of four genes (gapA, LP, mgc2, and pvpA). However, the field isolate, designated K5234,
differed significantly from the vaccine strain in field trials. The field isolate produced a much
stronger antibiotic response and colonized the trachea much more effectively than did the
vaccine strain (Throne-Steinlage et al., 2003). Thus, while the two strains were indistinguishable
RAPD and GTS, the 6/85-like strain had the interesting phenotypes of increased antibiotic
response, colonization, and persistence in experimental chickens.
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Using two-dimensional electrophoresis based quantitative expression proteomics, the
current study investigated the proteomic variations between strains 6/85 and K5234 in order to
develop a more comprehensive understanding of the molecular basis of M. gallisepticum
virulence and attenuation and thereby contribute to the optimization of control strategies.

Expression Proteomics
While the amount of genetic information is staggering (117 billion base pairs currently in
Genbank), there is a general acceptance that DNA sequences alone are inadequate when the goal
is to develop a global, real time understanding of biological systems (Beranova-Giorgianni,
2003). As genes may or may not be expressed, an organism‟s genome can be thought of as a
potential or a “blueprint” (Simpson, 2003). To a certain extent, mRNA also indicates a potential
physiological state; numerous modifications can take place above the level of transcription,
including post-transcriptional and translational modifications, proteolysis, protein degradation,
and compartmentalization (Graves and Haystead, 2002). Various studies have also revealed poor
correlations between mRNA levels and their corresponding protein levels (Ghaemmaghami et
al., 2003; Graves and Haystead, 2002; Ideker et al., 2001). On the other hand, proteins can be
thought of as actuality; they “mediate the greater part of cellular activities” and are directly
related to a cell‟s real time physiological state (Tannu and Hemby, 2006). As Richard J.
Simpson writes, proteins can be viewed as “bridges between genotype and phenotype” (Simpson,
2003).
The term proteome was originally defined as “the complete set of proteins that is
expressed, and modified following expression, by the entire genome in the lifetime of a cell”
(Wilkens et al., 1996). Currently, the most common definition of proteome is “the entire
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complement of proteins expressed by a cell at any one time,” a definition that reflects the
dynamic nature of protein expression (Anon., 1999). The goal of most non-targeted proteomic
research is to gain a more global understanding of biological systems by analyzing as many
proteins as possible. The global data can then be used as a platform for more targeted studies and
also be integrated with other “omic” (genomic, transciptomic, and metabolomics) data (Graves
and Haystead, 2002; Simpson, 2003). This approach forms the core of systems biology, a
discipline “which aim[s] at a systems level understanding of genetic or metabolic pathways by
investigation of interrelationships…and interactions…of genes proteins, and metabolites”
(Selinger, 2003; Wolkenhauer, 2001).
Proteomics can be divided into four broad areas: bioinformatic based proteomics,
structural proteomics, functional proteomics, and expression proteomics. Bioinformatic based
proteomics takes advantage of computational tools and resources to conduct in silico
experiments (Westermeier and Naven, 2002). The goal of structural proteomics is the analysis of
protein complexes. Functional proteomics is a general term used to describe more specific,
directed studies. Expression proteomics (or comparative protein profiling) is the quantitative
study of protein levels between two systems that differ by some variable (Graves and Haystead,
2002).
Two dimensional electrophoresis (2DE) / mass spectrometry (MS) based expression
proteomics is of particular value to the microbial cell physiologists interested in investigating
molecular mechanisms involved with phenotypic variations. By identifying proteins that vary in
abundance between two samples, it is possible to link certain proteins to observed phenotypic
variations, leading to the elucidation of molecular mechanisms responsible for processes of
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interest. For applied microbiologists, this increases the potential targets for affecting cellular
processes.
Two-dimensional electrophoresis was developed by O‟Farrell in 1975 (O‟Farrel, 1997).
The technique is used to resolves complex mixtures of proteins by separating the proteins
according to two independent characteristics: isoelectric point (pI) and molecular weight (MW).
In the first dimension, proteins are separated according to their pI using isoelectric focusing
(IEF). In the second dimension, proteins are separated according to their MW using sodium
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). After the proteins are
separated, variations in protein levels between the two samples are determined using image
analysis and quantification software. Proteins of interest are then characterized by MS.
Protein separation by 2DE can be broken down into four stages: sample preparation, IEF,
SDS-PAGE, and image analysis. As one scientist has noted, “[s]ample treatment is the key to
adequate [2DE] results” (Westermeier and Naven, 2002). Typically, cells are lysed directly into a
solubilization buffer that is compatible with IEF and will ensure high resolution. The buffer must
achieve the following tasks: convert all proteins into single conformations, cancel different
oxidation steps, disrupt protein aggregates, prevent protein modification, and disrupt hydrogen
and disulphide bonds. Additionally, the solubilization buffer must satisfy the constraints of IEF,
namely that conductive substances are kept to a minimum (Shaw and Riederer, 2003). Standard
solubilization buffers contain urea, a nonionic or zwitterionic detergent, a reductant, and carrier
ampholytes. Urea denatures proteins by disrupting hydrogen bonds and hydrophobic interactions,
converting proteins into single conformations. Nonionic detergents, such as NP-40 and Triton X100, and zwitterionic detergents, like 3-[3-(cholamidopropyl)dimethylammonio]-1-propane
sulfonate (CHAPS), prevent hydrophobic interactions and loss of protein due to aggregation and
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precipitation. Reductants cleave intra-and intermolecular disulphide bonds between cysteine
residues, converting them to sulfhydral groups. Carrier ampholytes minimize protein aggregation
due to charge-charge interactions and scavenge isocyanate, a urea derivative which is capable of
modifying proteins and thereby generating artificial protein spots. (Simpson, 2003; Westermeier
and Naven, 2002).
Once the proteins have been solubilized, they are applied directly to the first dimension
IEF gel. Isoelectric focusing takes advantage of the amphoteric nature of proteins. The net charge
of a protein is dependent on the pH of its environment. The pH of the environment where the net
charge of a protein is zero is called its isoelectric point (pI). If the pH of the environment is
above a protein‟s pI, then the protein will have a net negative charge. If the pH of the
environment is below a protein‟s pI, then the protein will have a net positive charge. When
placed in a pH gradient with a current, proteins will migrate toward the electrode opposite their
net charge, negatively charged proteins migrating toward the anode and positively charged
proteins migrating toward the cathode. Proteins will stop (focus) when the pH of the gradient
equals their pI, and they have no net charge (Westermeier and Naven, 2002).
Traditionally, IEF gel gradients were created with mixtures of carrier ampholytes, small
amphoteric buffers with isoelectric points over a broad range and high buffering capacities near
their pI. The ampholytes were mixed with low percent (so that there was no sieve effect)
acrylamide monomer, and a current was applied. The buffers migrated accordingly, forming a
pH gradient. This method was problematic for several reasons. During electrophoresis, the
gradients were unstable and would drift. Additionally, there was significant batch-to-batch
variability and gradients could not be extended above a pH of 7.5. Also, proteins could act as
ampholytes and modify the gradients, making the gel gradients sample specific (Simpson, 2003).
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Many of these problems were overcome with the development of immobilized pH
gradients (IPG) by Bjellqvist and coworkers (Bjellqvist et al., 1982). Immobilized pH gradients
use acrylamide derivatives instead of carrier ampholytes. The derivatives have carboxylic acid
and tertiary amino acid reactive groups. Typically, glycerol is added to a solution of the acidic
acrylamide buffer and linearly mixed with a solution of basic acrylamide buffer. Upon
polymerization, the reactive groups covalently bind the gel matrix. The gels are bound to a
support film, dried down, and then cut into strips. Because the gradient is bound to the gel
matrix, it is stable, and batch-to-batch variation is minimized. Immobilized pH gradient gels also
have a much higher loading capacity than traditional carrier ampholyte gels (Simpson, 2003).
After the first dimension and before the second dimension, the proteins in IEF gels need
to react completely with SDS, be re-reduced, and alkylated. This is achieved by equilibrating the
strips twice in a buffer containing SDS, urea, and glycerol. During the first equilibration,
dithiothreitol (DTT) is added to the equilibration buffer to ensure that all proteins are reduced.
Iodoacetamide is added to the second equilibration buffer to alkylate sulfhydral group,
preventing re-oxidation. Iodoacetamide also scavenges excess DTT (which can cause streaking)
and aids MS analysis (Gorg et al., 2000).
Isoelectric focusing gels are applied directly onto the tops of SDS-PAGE gels. Sodium
dodecyl sulphate polyacrylamide gel electrophoresis separates proteins according to their MW.
Gels are composed of polymerized acrylamide and N,N‟methylenebisacrylamide. During
electrophoresis, negatively charged SDS-protein complexes migrate toward the anode, with the
gel acting as a porous sieve. The migration distance of a protein is logarithmically related to its
MW. Low MW proteins will migrate further than high MW proteins (Westermeier, 2001).
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Theoretically, combining IEF and SDS-PAGE could separate up to 10,000 proteins. However,
only up to 2,000 proteins are routinely separated in laboratories (Gorg et al., 2004).
Once a protein extract has been separated by 2DE, MS is typically used to characterize
the proteins of interest. Mass spectrometry measures the relative MW of molecules by converting
them to gas phase ions and separating the ions according to their mass:charge (m/z) ratio. Most
MS instruments contain three modules: the ionization source, the mass analyzer, and the
detector. The ionization source converts the molecules into gaseous ions by adding protons or
subtracting electrons. The mass analyzer uses a magnetic or electric field to propel the ions
toward a detector which monitors the magnitude of the current from the ions as they reach the
end of the mass analyzer (Henzel et al., 2003).
Of the multiple MS configurations used in protein science, matrix assisted laser
desorption ionization–time of flight (MALDI-TOF) is one of the most simple, robust, and
amendable to high throughput (Aebersold, 2003). Typically, the sample is digested with trypsin,
and the peptide digest is co-crystallized with a matrix, which is a small organic molecule that
absorbs specific wavelengths of light. The dried sample is pulsed with UV light and energy is
transferred from the matrix to the analyte, causing desorption and ionization. The initial velocity
of an ion is dependent upon its mass, and an ion‟s time of flight in the analyzer is proportional to
the square root of its m/z ratio. Smaller molecules will reach the detector before larger
molecules. The MW of molecules in a complex mixture can be determined by comparing their
time of flight to that of a standard (Westermeier and Naven, 2002). Ultimately, a spectrum is
generated that contains the MW of each peptide fragments in the protein digest.
The MALDI-TOF can also be configured for tandem MS or MALDI-TOF/TOF. With
this configuration, two TOF analyzers are split by a collision cell. In the first analyzer, specific
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ions are selected and then energetically fragmented by collision-induced dissociation (CID) in
the collision cell. The fragments are then separated by the second TOF analyzer (Westermeier
and Naven, 2002). Matrix assisted laser desorption ionization–time of flight/time of flight
produces two types of data. The first type is called peptide mass fingerprints (PMF), which is a
spectrum generated from the MWs of the unfragmented tryptic peptide digests (MS data). A
protein is identified by comparing its experimental spectrum to those of theoretically digested
proteins in a database. The second type of data is sequence information deduced from the
fragmented peptides (MS/MS data). Usually, two or more fragment sequences are enough to
identify a protein (Henzel et al., 2003). The two types of data are used separately or in
conjunction to characterize a protein.
The current study used 2DE / MALDI-TOF/TOF MS in conjunction with difference gel
electrophoresis (DIGE) technology to quantify proteomic variations between two organisms.
Difference gel electrophoresis employs a set of three cyanine dyes (Unlu et al., 1997) and
computer software (Decyder) designed exclusively for use with these dyes. The three fluorescent
dyes (Cy™2, Cy™3, and Cy™5; Piscataway, NJ), which bind lysine, are matched for charge
and mass and are spectrally distinct. A protein labeled with each of the fluors will migrate to the
same position on a gel (co-migration). Images can be generated for each of the Cy™-labeled
samples, and differential data is generated by comparing the pixel intensities of the fluors
(Minden et al., 09; Tonge et al., 2001). Typically, control and variant samples are labeled with
either Cy™3 or Cy™5. In practice, reverse-labeling may be employed to cancel any protein
specific variation in labeling between the two dyes. A standard sample (internal standard)
containing equal amounts of protein from each sample in the experiment is labeled with Cy™2.
After the labeling reaction, the three Cy™- labeled samples are mixed together (multiplexed) and
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then separated by 2DE (Fig. 4, p. 18; Fig. 5, p. 19). Because each dye has different excitation
/emission requirements, one image for each of the multiplexed samples can be generated (Alban
et al., 2003).
The inclusion of an internal standard offers several advantages. First, a direct ratio of
each protein spot to its representative internal standard on the same gel can be derived (intra-gel
analysis). This ratio can then be compared with the ratios of the same spot on different gels
(inter-gel analysis), allowing the detection of small changes above experimental and biological
variation to be detected with high statistical significance (DeCyder, Version 5.0). The internal
standard also facilitates gel matching. With conventional systems, different samples from
different gels have to be matched. With the DIGE system, the internal sample is the same sample
on each gel, making matching easier and more accurate (DeCyder, Version 5.0).

Objectives
The goal of the current project was to identify proteomic variation between a M.
gallisepticum vaccine strain (6/85) and a closely related virulent, field isolate (K5234) which
varied in phenotypes of medical relevance. The project was deemed well suited for 2DE /
MALDI-TOF/TOF MS based proteomics for several reasons. In order to characterize a protein
using MALDI-TOF/TOF MS, the protein‟s gene has to have been sequenced. The M.
gallisepticum prototype strain, Rlow, has been completely sequenced. It contains a 1,012,80 bp
genome with 784 genes, 469 of which have been functionalized (Papazisi et al., 2003;
Szczepanek et al., 2010). Because of M. gallisepticum’s small genome, 2DE would provide a
high percent coverage of the M. gallisepticum proteome. Also, because the two strains being
compared had very similar genomes (as determined in the preliminary evaluations), the data set
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was predicted to be manageable, enabling some of the protein level variations to be linked to the
observed phenotypic variations between the two strains. The objectives of the project were first
to identify proteins that varied in abundance between 6/85 and K5234 using 2DE, and then to
characterize these proteins by MALDI-TOF/TOF MS. It was hypothesized that some of the
identified proteins could be implicated in the increased colonization and virulence of K5234,
thereby shedding light on the mechanisms employed by M. gallisepticum during the infection of
its host.
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Fig. 1. Phylogeny of Firmicutes. Mollicutes branched off from the low GC gram-positive
bacteria (Wolf et al., 2004).
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Fig. 2. Phylogeny of mollicutes. M. gallisepticum is in the same phylogenetic cluster as M.
pneumoniae and M. genitalium, the two most well-studied mollicutes (Barre et al., 2004).
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Table 1. Selected sequenced mollicutes. Species listed in order of increasing genomic size
(Barre et al., 2004).
Organism

Associated disease ( host)

kb

Genes

Urogenital or respiratory tract infection (human)

580

484

Aster yellows / witches‟-broom (plant)

707

671

Septicaemia / meningitis / pneumaonia (human)

752

614

(fish)

777

667

(animal)

793

683

Chronic respiratory disease / synovitis (poultry)

799

672

M. pneumonia

Atypical pneumonia (human)

816

689

Candidatus asteris OY

Onion yellow disease (plant)

861

754

Contagious aglactia (small ruminant)

877

752

Pleuropneumonia (swine)

691

691

M. hypneumoniae J

Enzootic pneumonia (swine)

897

665

M. hypneumoniae 7448

Enzootic pneumonia (swine)

920

663

Respiratory infection (murine)

964

782

Chronic respiratory disease (poultry and turkey)

996

726

Severe arthritis / septicemia (animal)

1010

827

Pleuropneumonia (cattle)

1212

1016

Urogenital and respiratory tract infections (human) 1359

1037

M. genitalium
Candidatus AY-WB
Ureaplasma urealyticum
M. mobile
Mesoplasma flurum
M. synoviae

M. agalactiae
M. hypneumoniae 232

M. pulmonis
M. gallisepticum
M. capricolum
M. mycoides
M. penetrans
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Fig. 3. M. gallisepticum cell morphology (Barre et al., 2004).
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CHAPTER 2
EXPERIMENTAL OVERVIEW AND MATERIALS AND METHODS

Experimental overview
Mycoplasma gallisepticum 6/85 and K5234 were grown under identical conditions and
harvested during mid-exponential phase. Cells were mechanically disrupted and a crude, soluble
protein extract was prepared. Protein extracts from four biological replicates of each strain were
individually labeled with Cy™ dyes. According to best laboratory practice, reverse-labeling (dye
swaps or flip dye) was employed. Half of the 6/85 extracts were labeled with Cy™2 and half
were labeled with Cy™5. K5234 extracts were labeled similarly. A standard sample was
prepared by mixing equal amounts of protein from each of the eight extracts. The standard was
labeled with Cy™2. The samples were multiplexed by combining one Cy™3 sample, one
Cy™5, and one Cy™2 standard sample. The four multiplexed samples, along with an unlabeled
standard sample (a preparative load) were separated by 2-DE, using both 3-7NL and 7-11 IEF
strips. Variations in protein levels between the two cell types were determined using Decyder™
Differential Analysis Software, Version 5.0. Proteins that varied in abundance above 1.5 fold or
below -1.5 fold and with p-values below 0.01 were located on a preparative gel. Proteins of
interest were picked and then characterized by MALDI-TOF/TOF MS.
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Materials and Methods
Except where otherwise indicated, all reagents were purchased from Sigma-Aldrich.
Samples for both 4-7NL and 7-11 gel sets were derived from the same protein extracts. Identical
methods and conditions were used for both gel sets.
Cell growth. Mycoplasma gallisepticum strains 6/85 and K5234 were cultivated in
Frey‟s medium (Throne-Steinlage et al., 2003) at 37°C. Starter cultures (10 ml Frey‟s medium)
were inoculated with 100 µl of glycerol stock and incubated for 14 h. For each strain, 1.25 ml of
the starter cultures were used to inoculate each of four 1-L flasks containing 450 ml of media.
The cultures were incubated at 37°C and 100 rpm in a NBS Gyratory shaker (New Brunswick,
NJ). Cell growth was monitored by plate counts and OD600/640. According to previously
established growth curves, the cultures were harvested by centrifugation (3,000 x g for 20 min at
4°C) during mid-exponential phase (18 h). The cell pellets were washed three times in 10 mM
tris(hydroxymethyl)aminomethane chloride (TrisCl), pH 8.8, and 5 mM magnesium acetate. The
pellets were stored at -70°C.
Preparation of lyses buffer. Twelve grams of urea and 4.5 g of thiourea were dissolved
in 12 ml of ddH2O. The volume was made up to 25 ml with ddH2O, giving a solution of 8 M
urea and 2.3 M thiourea. To this solution, 250 mg of PlusOne™ Amberlite IRN-150L (GE
Healthcare) were added, and the suspension was stirred for 1 h on a magnetic stirrer and then
filtered through a 0.45-µm filter (Millipore). The following components were added to 13.2 ml
of the de-ionized urea / thiourea solution: 450 µl of 1 M Tris, 150 µl of nuclease mix (GE
Healthcare), 300 µl of protease inhibitor mix (GE Healthcare), and 600 mg of 3-[(3Cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS). The pH was adjusted to 8.6
with concentrated hydrochloric acid. The lyses buffer was diluted to 15 ml with ddH2O, making
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the final concentration: 30 mM Tris, 7 M urea, 2 M thiourea, 4% CHAPS, 1% nuclease mix (GE
Healthcare), and 2% protease mix (GE Healthcare). The lyses buffer was aliquoted in 1mlcryovials and stored at -70ºC for a maximum of 3 months.
Soluble protein extract. Nine hundred milliliters of lyses buffer were added to each cell
pellet. The samples were vortexed vigorously and then incubated on ice for 10 min. The cell
slurries were transferred to 50 ml glass centrifuge tubes and sonicated (Sonicator® Ultrasonic
Processor XL, Misonix) on ice six times (15 s on followed by 15 s off) using a 50% duty cycle.
Following sonication, the samples were incubated at room temperature for 1 h and then clarified
by centrifugation (40,000 x g for 1 h at 7°C). Protein concentrations were determined using a 2D Quant Kit (GE Healthcare). The clarified lysates were stored at -70°C until labeling.
Minimal CyDye™ labeling. The 6/85 (control) and K5234 (variant) samples were
diluted with lyses buffer to a protein concentration of 5 mg/ml in a volume of 75 µl. A pooled
sample, containing equal amounts of protein from each sample, was generated by mixing
together 55 µl of each of the eight samples. For the preparative gels, 40 µl (200 µg) of the
standard were transferred to a reaction tube. For the analytical gels, 10 µl (50 µg) of each of the
control/variants samples were transferred to separate reaction tubes.
CyDye™ DIGE fluors (GE Healthcare) were reconstituted according to the
manufacturer‟s instructions. Un-opened 10 mM dyes were thawed on ice for 5 min. Ten
microliters of N,N-dimethylformanide (DMF) were added to each dye, making the final
concentration 1 mM. The dyes stocks were vortexed vigorously for 30 s, centrifuged briefly, and
stored at -20°C.
The labeling reactions were carried out on ice and protected from light according to the
manufacturer‟s protocol. Working dye solutions consisted of 3 µl of the 1 mM dye stocks and
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4.5 µl of DMF, giving a final dye concentration of 400 µM. The control and variant biological
replicates were reverse-labeled. Half of the controls samples were labeled with 1 µl of Cy™3
(400pmol), and the other half were labeled with 1 µl of Cy™5. The variant samples were labeled
similarly. Four microliters of Cy™2 were added to reaction tubes which contained 40 ul of the
pooled sample. The samples were incubated for 30 min, and then the reactions were quenched
with 1 µl of 10 mM lysine. The samples were incubated for an additional 10 min and then stored
at -70°C.
Sample reduction. Multiplexed sample sets for each of four analytical gels were made
by marrying a Cy™3, Cy™5, and Cy™2 labeled sample (50 µg 6/85, 50 µg K3234, and 50 µg
standard - a total of 150 µg of protein). Equal volumes of 2X sample buffer - 7 M urea, 2 M
thiourea, 4% CHAPS, 10 mM dithiothreitol (DTT), and 2% 3-11 non-linear ampholytes (GE
Healthcare) - were added to each of the multiplexed samples. The preparative gel sample loads
were reduced by adding equal volumes of 2X sample buffer to 200 µg of the pooled samples.
The samples were vortexed and then incubated on ice for 30 min protected from light.
Two-dimensional electrophoresis. The proteins were separated by 2DE according to the
methods of O‟Farrel, as modified by Gorg et al., and described by Westermeier (O‟Farrel, 1975;
Gorg et al., 2000; Westermeier and Naven, 2002). Using a reswelling tray (GE Healthcare), IPG
strips (GE Healthcare) were rehydrated for 24 h in Destreak™ Rehydration Solution (GE
Healthcare). For both 4-7NL and 7-11 IPGstrips, the rehydration solution was supplemented with
1.0% 3-11NL ampholytes (GE Healthcare). The rehydrated strips were transferred to cup loading
strip holders (GE Healthcare), oriented so that the plastic backing was down and the gel face up.
The strips were covered with 4.4 ml of mineral oil. Electrode pads moistened with 150 ul of
ddH2O were placed at the ends of the gels. Protein samples were loaded at the acidic end of the
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strips via sample cups. The strips were focused for ~ 50, 000 volt/h (4 h at 300 V, 6 h gradient
from 300 V to 1,000 V, 3 h gradient from 1,000 V to 8,000 V, and 4 h at 8,000 V) using an
Ettan™ IPGphor™ Isoelectric Focusing System (GE Healthcare). The focused strips were stored
in plastic tubes at -70°C.
Casting second dimension SDS-PAGE gels. Low fluorescent glass gel plates (GE
Healthcare) were soaked in 1% Contrad (Fisher Scientific), rinsed with ddH2O, and polished
with 200 proof ethanol prior to casting. Prior to ethanol polishing, plates previously used to cast
bound gels were soaked in 1% HCL to hydrolyze residual bind-saline. The preparative gel
sandwich back plates were treated with 4 ml of a bind solution containing 8 ml of 100% ethanol,
1.8 ml of ddH2O, 200 µl of glacial acetic acid, and 12.5 µl of bind-saline (GE Healthcare). The
bind solution was evenly spread over each back plate using Crewipes (Kimberly-Clark). After 2
h, fluorescent picking references (GE Healthcare) were placed on the back plates. Analytical and
preparative gel sandwiches were assembled and loaded into a caster. A feed tube stem was
inserted into the displacing solution reservoir, which was then filled with 90 ml of displacing
solution (0.375 M TrisCl pH 8.8, 50% glycerol, and 0.002% bromophenol blue). A 12.5%
acrylamide gel solution - containing 294 ml 40% monomer (GE Healthcare), 235 ml 1.5 M
TrisCl (pH 8.8), 392 ml ddH2O, 9.4 ml 10% sodium dodecyl sulfate (SDS), 376 µl N, N, N’, N,tetramethylethylethylenediamine (TEMED), and 9.6 ml ammonium persulfate (APS) - was
prepared and poured into a funnel attached to the feed tube. The feed tube was removed, and the
level of the gel solution was adjusted by adding additional displacing solution to the reservoir.
The gels were allowed to polymerize for 2 h. After polymerization, excess polymer was trimmed
from the edges of the plates, and the gel sandwiches were rinsed thoroughly with ddH20. The gel
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surfaces were covered with gel storage solution (0.375 M TrisCl, pH 8.8, 0.1% SDS), wrapped in
plastic seal wrap, and then incubated overnight at room temperature before use.
Strip equilibration and second dimension. The IPG strips were thawed for 10 min at
room temperature and then incubated twice in 20 ml of equilibration buffer (EB: 50 mM TrisCl,
pH 8.8, 6 M urea, 30% glycerol, 2% SDS, 0.002% bromophenol blue) for 10 min at room
temperature with shaking (80 rpm). During the first equilibration, the proteins were reduced by
supplementing the EB with 0.5% DTT. During the second equilibration, the proteins were
alkylated by supplementing the EB with 4.5 % iodoacetamide.
The gel sandwiches were rinsed with ddH2O and inverted in a plate rack to drain excess
liquid from the gel surfaces. Using forceps, the IPG strips were rinsed with electrophoresis
running buffer (25 mM TrisCl, pH 8.3, 192 mM glycine, and 0.2% SDS), placed on the shelf of
the gel sandwich (plastic backing against the back plate), and situated along the top of the second
dimension gel using a plastic ruler. One milliliter of agarose sealing solution was added to the
gel sandwiches. The proteins were separated (20W per gel at 20ºC until the dye fronts migrated
off the gels) using an Ettan™ Dalt Twelve Large Format Vertical System (GE Healthcare) in the
running buffer previously described. Analytical gels were imaged immediately. The top plates of
the preparative gels were removed, and the gel bound bottom plates were placed in fixing
solution (7.5% acetic acid, 10% methanol) in preparation for staining.
Staining of preparative gels. The preparative gels were incubated overnight in fixing
solution and then stained with Deep Purple™ (GE Healthcare) according to the manufacturer‟s
instructions. The gels were transferred directly from the fixing solution into a wash solution (35
mM sodium bicarbonate and 300 mM sodium carbonate) and incubated for 30 min with gentle
shaking (25 rpm). After washing, the gels were incubated in 1 L ddH2O for 5 min at 25 rpm. The
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gels were then covered with 500 ml of a 200-fold dilution of Deep Purple™ stain and incubated
in the dark for 1 h at 40 rpm. The gels were then incubated in 1 L of stabilization solution (7.5%
acetic acid) for 1 h prior to imaging.
Scanning analytical gels. The gels were imaged with a Typhoon™ 9410 (GE
Healthcare). Prior to scanning, the gel sandwiches were rinsed with ddH2O and then dried
completely. The scanner window was cleaned thoroughly with three rounds of 200 proof ethanol
followed by ddH2O. The gels were placed in the scanner oriented so that the top plate was up, the
IEF strip was to the left, and the acidic portion of the gel was toward the user. The recommended
emission filter / laser combinations were used for each dye.
A pre-scan at 1000 microns pixel intensity was conducted to optimize the PMT voltages
for each fluor. The auto link mode was set to sensitivity, and the sensitivity was set to normal.
The gels were scanned, and the PMT voltages were adjusted so that any increase in voltage
resulted in the appearance of red saturation spots. Ten units were subtracted from this voltage,
and it was used for scanning at 100 microns. The images were cropped using ImageQuant
software, and the resulting 16-bit Tiff files were exported to Decyder™ Differential Analysis
Software, Version 5.0 (GE Healthcare) for analysis.
Scanning preparative gels. While submerged in stabilization solution, cleaned glass top
plates were lowed at an angle (to prevent trapping large bubbles) onto the top faces of the
adhered preparative gels and then incubated for 5 min, allowing the top plates to stick to the gel
surfaces. Prior to scanning, the gel sandwiches were rinsed with ddH2O and then dried with
Crewipes. Pre-scans were conducted as per analytical gels using the Green (532) laser and the
560LP emission filter. Images were acquired at optimized PMT voltages at 100 microns pixel
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intensity and then exported to quantitative analysis software. The gel sandwiches were stored in
stabilization solution at 4C until spot picking.
Decyder™: analysis of analytical gels. The quantification of variations in protein levels
between strains 6/85 and K5234 using DeCyder™ (GE Healthcare) was carried out, essentially,
according to the user manual. For individual gels, the Differential In-gel Analysis (DIA) module
was used to establish spot boundaries, convert pixel intensities to volumetric units, filter the
images, normalize Cy™3 labeled and Cy™5 labeled samples against the Cy™2 internal
standard, and calculate spot volume ratios. The Biological Variation Analysis (BVA) module
was used for gel matching and the statistical analysis of variations.
DIA: sequential intra-gel analysis. Individually, the three images from each gel were
opened in the DIA module. A value of 4,000 estimated spots was used. Spot detection and
quantification was carried out with the triple detection function. A light filter using parameters
established by GE Healthcare (slope, 1.1; area, 100; peak height, 100; and volume, 10,000) was
applied.
BVA: simultaneous inter-gel analysis. Each image was assigned as an analysis image.
The Cy™2 standard image with the most spots was assigned as the master image. For the
purpose of statistical analysis, each image was assigned to one of three experimental groups: the
two Cy™3 6/85 and the two Cy™5 6/85 images were assigned as controls, the two Cy™3
K5234 and the two Cy™5 K5234 images were assigned as variants, and the four Cy™2 standard
images were assigned as standards. Extensive manual spot merging and land marking were
conducted across the entire gel set. Spots were then matched. The matched images were
intensively scrutinized, and incorrect matches were corrected manually. Statistical data was
generated using a Student‟s T-test. The results were filtered by assigning all spots with a T-test
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score below 0.01 and an average ratio above 1.5 or below -1.5 as proteins of interest. Each
protein of interest was scrutinized again to ensure proper matching and spot boundary
assignment.
Analysis of preparative gels. The preparative gel images were analyzed in the DIA
module as per analytical gels using the single detection function. The gel images were
incorporated into the previously established BVA file and assigned as pick gels. The location and
size of the picking references were, if necessary, adjusted. Spots were merged where necessary,
and the images were extensively landmarked against the master analytical images. The
preparative images were then matched to the analytical gel set. Spots of interest that were
correctly matched or could be manually matched to spots on the preparative image were assigned
a pick status. The x and y coordinates of the confirmed spots were saved as a pick list.
Spot picking. Using an Ettan™ Spot Picker (GE Healthcare), the spots of interest were
excised from the preparative gels according to the manufacturer‟s instructions. The top plates
were removed from the gel sandwiches. The bound gels were appropriately oriented in the gel
tray and covered with ddH2O. The picker was primed 20 times with HPLC grade H2O. Z-heights
were determined for each gel. The gel plugs were transferred to low protein bind 96-well-plates
(GE Healthcare) previously rinsed with ddH2O. After picking, the water was removed from the
wells, and the plugs were stored at 4°C until processing for MS.
Protein digestion. Protein digestion was carried out in the 96-well-plates. The gel plugs
were incubated twice for 20 min in 100 µl of a wash solution containing 5mM ammonium
bicarbonate and 50% acetonitrile (Applied Biosystems). The wash solution was removed, and
100 µl of 75% acetonitrile were added to each well. The samples were incubated for 20 min.
The acetonitrile was removed, and the plugs were dried for 30 min in a speedvac. The 96-well-
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plates containing the dehydrated plugs were handled with care to avoid sample loss due to static
electricity. Seven microliters of fresh 20 µg/ml trypsin (Promega) in 20mM ammonium
bicarbonate were added to the dehydrated plugs. The samples were incubated over night at 37°C.
After digestion, 60 µl of 50% acetonitrile / 0.1% trifluoroacetic acid (TFA) was added to each
well. The 96-well-plates were incubated for 20 min. The extracted peptides were transferred to
low protein bind microfuge tubes (Fisher Scientific), and the extraction was repeated with 40 µl
of the extraction solution. The second extracts were married to the first. The samples were dried
down in a speedvac and stored at -20°C until de-salting.
De-salting. The dried down samples were solubilized in 1.5 µl of formic acid with
vigorous vortexing. The volumes were brought up to 10 µl with 8.5 µl of 0.1% TFA. The
samples were again vortexed and then centrifuged briefly. Samples were de-salted with µC18
ZipTips (Fisher Scientific) according to the manufacturer‟s instructions. The microtip columns
were prepped by aspirating and dispensing 10 ul of wetting solution (50% acetonitrile in ddH2O)
twice and then equilibrated with ten rounds of 0.1% TFA. The samples were bound to the
column by aspirating and despising the samples seven times. The bound peptides were then
washed ten times with 10 µl of 1% TFA. The samples were eluted with 0.7 µl of elution solution
(0.1% TFA and 70% acetonitrile) and spotted onto MS target plates. The spotted samples were
allowed to partially dry, and then 0.3 µl of alpha matrix (Applied Biosystems) were added to
each. The target plates were stored at room temperature protected from light until MS analysis.
Mass spectrometry. Mass spectrometry was conducted by the Macrochemical Facility at
Emory University using an Applied Biosystems 4700 MALDI-TOF/TOF. The combined MS and
MS/MS data was searched against the NCBInr database using the Mascot search engine. A
protein score C.I. above 95% indicated identification or extensive homology.
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CHAPTER 3
RESULTS

A total of over 1,000 spots were included in the 2DE analysis. This number may seem
high for an organism containing only 742 genes, but it has been predicted that for prokaryotes
1.5 protein species exist for each gene (Simpson, 2003). Also, it must be kept in mind that a
number of the spots were redundant, appearing in the overlapping region (ph 7) of the two types
of IEF strips used, and that some spots were inevitably artifacts. Sixty-eight spots from the
analytical gel sets showed fold changes above 1.5 or below -1.5 and had p-values below 0.01.
Sixty of these spots were located as isolated spots on preparative gels and were subjected to
MALDI-TOF/TOF for characterization. The digests from eight of these spots did not result in
protein match scores indicative of identification, and four identifications were ambiguous. The
remaining forty-eight digests had protein scores indicative of extensive homology or
identification, forty of which, representing 29 different proteins, were identified as M.
gallisepticum strain Rlow protein species. These results are organized in Table 2 (p. 33). Fold
changes are relative to K5234, positive numbers indicating an increased abundance in K5234 and
negative numbers indicating a decreased abundance in K5234. Nine proteins appeared as
multiple spots (multiple species). These included AtpD (ATP synthase beta chain), Lpd
(dihydrolipoamide dehydrogenase), AcoA (pyruvate dehydrogenase), Mdh (lactate
dehydrogenase), Smc-like protein (chromosome segregation ATPase), FusA (translation
elongation factor G), MgpA-like protein (exopolyphosphatase related), HcaD (NADH oxidase),
and a conserved hypothetical lipoprotein. All of the multiple forms of a given protein had the
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same fold change direction. Twelve of the twenty-nine proteins increased in abundance, and 17
decreased. The highest positive fold change was 19.57 (one of the three AtpD species) and the
lowest negative fold change was -9.13 (one of the two pyruvate dehydrogenase species). AtpA
was the only protein of interest to appear on both 4-7NL and 7-11 gel sets.
Sixteen proteins of interest belong to COGs (Clusters of Orthologous Groups). The
COGs represented include: [C] energy production and conversion, [D] cell division and
chromosome partitioning, [F] nucleotide transport and metabolism, [G] carbohydrate transport
and metabolism, [J] translation and ribosomal structure biogenesis, [K] transcription, [R] general
prediction only, and [T] signal transduction. The most well represented COG is [C] energy
production and conversion, with six proteins. Thirteen proteins of interest have no COG. Proteins
with no COG represent 39% of the predicted M. gallisepticum proteome.
It should be mentioned that COGs are phylogenetic and not necessarily functional
organizational tools. This discrepancy seems to be accentuated in mollicutes. Many of the
activities typically associated with proteins encoded by mollicute genomes have not been
detected in mollicutes. Some mollicute proteins have alternative or additional functions
(bifunctionality) that are not reflected by their functional assignment. Additionally, some
processes common to bacteria are mediated by proteins that have evolved independently in
mollicutes and are thus phylogenetically unrelated to proteins that mediate similar processes in
other bacteria. Functional classification is further complicated by significant protein functional
variability within class Mollicute (Pollock, 2002).
Three of the unclassified proteins are considered virulence factors. These include GapA
(M. gallisepticum adherence protein A), CrmA (cytadherence related molecule A), and
VlhA.3.09 (pMGA family protein) – all three of which had increased levels in the virulent field
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strain. Three proteins of interest are conserved hypothetical proteins, and three are unique
hypothetical proteins. Generally, proteins associated with virulence increased in abundance in
the virulent K5234, while metabolic proteins decreased in abundance in K5234.
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Table 2. Differential and MS data. Fold changes are relative to K5234 (the virulent field isolate). Positive numbers indicate
increased abundance in K5234, and negative numbers indicate decreased abundance in K5234. (-) indicates multiple forms of the
same protein, except in the case of AtpA, which appeared in both experimental sets (Tatusov et al., 2001; Barre et al., 2004).
Protein

Description

Locus

Accession # Fold ∆

p-value

MS
C.I.%

AtpD
AtpA (4-7)
(7-11)
Lpd
AcoA
Mdh
AceF

[C] Energy production and conversion
ATP synthase beta chain
MGA_491
ATP synthase alpha chain
MGA_488
Dihydrolipoamide Dehydrogenase
MGA_161
Pyruvate dehydrogenase
MGA_165
L-lactate Dehydrogenase
MGA_746
Dihydrolipoamide acetyltransferase
MGA_162

31541707
31541706
31541532
31541535
31541121
31541533

19.57
11.19
6.02
3.76
3.09
2.61
2.60
-9.13
-4.13
-1.85
-1.71
-1.71

7.6x10-5
1.5x10-5
2.2x10-6
7.5x10-6
1.9x10-4
6.3x10-6
1.5x10-5
1.6x10-6
5.0x10-3
7.3x10-6
3.0x10-3
3.2x10-8

98.3
100
100
100
100
100
100
100
99.7
100
100
100

Smc-like
FtsZ

[D] Cell division and chromosome partitioning
Chromosome segregation ATPase
MGA_917
31541218
Cell division protein
MGA_27
31541447

1.98
1.86
-1.60

4.9x10-7
2.6x10-5
3.6x10-6

100
100
100

NrdF
NrdA

[F] Nucleotide transport and metabolism
Ribonucleotide reductase beta subunit
MGA_698
31541093
Ribonucleotide reductase alpha subunit
MGA_695
31541091

-2.84
-1.97

5.0x10-5
1.3x10-5

100
100

[G] Carbohydrate transport and metabolism
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Eno

Enolase

31541555

-2.63

1.2x10-3

100

FusA
-

[J] Translation, ribosomal structure biogenesis
Translation elongation factor G
MGA_260
31541582
-

1.71
1.54

8.3x00-5
1.6x10-4

100
100

NusA

[K] Transcription
N-utilization substance protein A homolog
MGA_818

1.57

1.6x10-4

100

MGA_209

31541161

[R] General prediction only
MgpA-like
Exopolyphosphatase related
MGA_683
Predicted GTPase
MGA_500

31541085
31541712

-1.97
-1.65
-1.56

7.3x10-8
6.8x10-6
3.4x10-7

100
99.8
100

PTC1

[T] Signal transduction
Protein serine/threonine phosphatase
MGA_461

31541689

-1.89

5.5x10-6

100

CrmA
GapA
TrxB
Gmk
HcaD
GryB
VlhA.3.09

Unclassified
Cytadherence related molecule A
M. gallisepticum adherence protein A
Thioredoxin reductase
Guanylate kinase
NADH oxidase
DNA gyrase (topoisomerase) B subunit
pMGA family protein; similar to pMGA1.4.1.3

MGA_616
MGA_395

31541229
31541228
31541379
31541690
31541536
31541775
31541647

3.88
2.17
1.91
-1.61
-1.60
-1.60
-1.56
-3.70

7.1x10-8
3.9x10-3
4.6x10-7
7.2x10-3
1.8x10-4
5.8x10-6
1.6x10-4
9.9x10-5

100
100
100
100
99.4
100
100
100

Conserved hypothetical
MGA_267
MGA_674
MGA_1203

31541586
31541080
31541370

1.91
1.73
-1.63
-1.59

4.4x10-7
5.8x10-7
2.2x10-3
2.2x10-5

100
100
100
98.3

Conserved hypothetical, lipoprotein
Conserved hypothetical, lipoprotein
Conserved hypothetical (Hlp2)

MGA_939
MGA_934
MGA_1221
MGA_462
MGA_167
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Unique hypothetical (COG)
Unique hypothetical
Unique hypothetical

Unique hypothetical
MGA_480
MGA_573
MGA_1071

31541701
31541754
31541293

2.50
1.82
-2.10

1.2x10-3
1.6x10-6
7.2x10-6

100
100
99.1
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CHAPTER 4
DISCUSSION

Phase / antigenic variation and VlhA
The ability of bacterial populations to persist or proliferate in constantly changing
environments is often based on their ability to vary phenotypes (phenotypic plasticity), either in
response to environmental cues or by random mutations. Phenotypic variation via environmental
sensing is typically achieved through a mechanism whereby an organism “samples” its
environment and adjusts its phenotype accordingly via a sensor/response regulator system
(Rottom, 2003). For example, Pseudomonas aeruginosa is thought to switch between a virulent,
free-living state and a less virulent but more persistent biofilm state in response to available
nutrient and energy sources (O‟Toole, 2004).
An alternative means of phenotypic variation employed by many bacteria, especially
those with limited genetic capacities and few regulatory proteins, is phase or antigenic variation.
Generally, both phase and antigenic variation refer to the ability of an organism to alternate
between phenotypes in a “heritable and reversible manner” (van der Woude and Baumler, 2004).
Within this broad definition, specific definitions of phase and antigenic variation continue to
evolve as more relevant data is produced. The most contemporary use of „phase variation‟ refers
to the oscillation of a gene between all „on‟ and all „off‟ states. In contrast, „antigenic variation‟
refers to the oscillation between different antigenic forms. Sometimes this involves gene
families, which can act as archives of epitopes, expressing only one epitope at a time (van der
Woude, 2006). Simplistically, with the former, the protein is either present or absent, and with
the latter, the protein or structure is typically present but in different forms.
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Both phase and antigenic variation generate heterogeneous populations of clonal variants
by high frequency random mutations which occur as replication errors. The phase of the parent
cell is passed along to the daughter cell, which can then generate revertants. While the mutations
are thought to be random and thus non-responsive to the environment, the frequencies of the
mutations can be modulated, and current research indicates that phase variation may be
integrated into regulatory networks that are environmentally responsive. The functions of
structures that undergo phase/antigenic variation vary, but most are antigenic surface structures
(i.e. surface appendages and lipoproteins) or enzymes involved with modifying these surface
structures (van der Woude, 2006). The biological significance of phase/antigenic variation is
most commonly thought to endow pathogens with a means of evading host immune responses,
which target individual cells expressing dominate antigenic forms while allowing subpopulations
of antigenic variants to escape and proliferate, causing chronic infections (Frank and Barbour,
2006; Lipsitch and O‟ Hagan, 2007). Recent studies indicate that phase/antigenic variation is not
limited to host/pathogen interactions but can also be the bases of numerous adaptive processes,
including niche exploitation (van der Woude, 2006). In the current study, three of the virulence
factors (VlhA, GapA, and CrmA) that varied in abundance undergo phase and/or antigenic
variation.
VlhA (previously designated pMGA), a family of surface lipoproteins, is the
immunodominant antigen of M. gallisepticum recognized by chicken antibodies. VlhAs are
hemmagluttinins and have been shown to undergo both phase and antigenic variation in vitro and
in vivo (Bradbury, 2005; Markham et al., 1992). Mycoplasma gallisepticum strains analyzed thus
far have VlhA families consisting of from 32 to 51 genes, attesting to its importance to M.
gallisepticum survival (Basseggio et al., 1996). The prototype stain Rlow has 49 vlhA genes
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(Szczepanek et al., 2010). Early studies interpreted the presence of different vlhA transcripts
within a single population as multiple vlhA transcription at the cellular level (Glew et al., 1995);
however, current studies indicate that the expression of different VlhA paralogues within a
population results from small subpopulations that happen to express different family members,
and that at the cellular level only one family member is transcribed at any given time (Liu et al.,
2000).
In vitro expression of VlhA in isogenic lineages oscillates in response to the presence or
absence of VlhA directed antibodies. Markham et al. demonstrated that when grown in the
presence of an antibody directed at VlhA1.1 (the designation of the predominate VlhA protein
expressed in culture without antibody pressure), M. gallisepticum S6 ceased expressing VlhA1.1
and immediately began expressing a secondary, antigenically distinct family member, designated
VlhA1.9. When the VlhA1.9+ progenitor cells were transferred back into media lacking the
antibody, the population ceased expressing VlhA1.9 and reverted to the phenotype of the founder
cells (Markham et al., 1998). Glew et al. observed a slightly different scenario in vivo. Chickens
were inoculated with strain S6, and six days post infection the majority of the recovered cells
ceased to express any VlhA family member. Only after prolonged incubation did a population
arise that expressed a paralogue different from that of the inoculant. Thus, a phase variant
dominated the acute stage of infection, while an antigenic variant dominated the chronic stage of
infection. Interestingly, unlike the in vitro study mentioned above, the in vivo variant population
arose and proliferated prior to the appearance of detectable antibodies. The authors hypothesized
that there might have been some growth advantage that selected for the VlhA phase variant
(Glew et al., 2000). The nature of these phenotypic switches was shown to be transcriptional,
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involving high frequency alterations in the number of short tandem GAA repeats in the
intergenic regions of vlhA family members (Glew et al., 1998; Liu et al., 1998; Liu et al., 2000).
A recent analysis of global transcript variations between M. gallisepticum cells grown in
broth versus cells grown in association with eukaryotic cells showed that one VlhA paralogue
was up-regulated 2.41 fold in cells grown in association with eukaryotic cells (Cecchini et al.,
2007). Interestingly, by setting the incubation time below that of a generation time, the study was
designed in way as to negate the influence of phase/antigenic variation and only include
variations resulting from transcriptional regulation in response to environmental cues. A genomic
comparison of the virulent Rlow strain with the attenuated F strain revealed that the vlhA locus
was the most highly variable genomic region between the two strains, with F strain containing 28
fewer family members than Rlow (Szczepanek et al., 2010). This data further supports the
involvement of VlhA in the adaptation of M. gallisepticum to its environment.
In the current study, the attenuated vaccine strain (6/85) expressed 3.7 fold more
VlhA.3.09 than did the virulent 6/85-like field isolate (K5234); no other VlhA appeared in the
data set. As previously mentioned, individual M. gallisepticum cells express only one or no VlhA
family member at any given time , and other than being all „on‟ or all „off‟ (Liu et al., 2000),
there are no reports of M. gallisepticum cells varying the expression of any one family member.
Likewise, there are no reports which indicate that, at the cellular level, one strain of M.
gallisepticum produces significantly more or less VlhA than another strain. So while it cannot be
dismissed that individual 6/85 cells may have simply contained more VlhA.3.09 than K5234
cells, it is more likely that the experimental variations occurred at the population level: more
cells in the 6/85 population expressed VlhA.3.09 than did cells in the K5234 populations. With
this in mind, one possible scenario to account for the experimental variation is that VlhA.3.09
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could have been the predominant (that member expressed in the absence of antibodies) family
member expressed by 6/85 populations and only a secondary family member expressed by
K5234 populations. In this case, K5234 may have expressed its predominant VlhA in higher
levels than the same family member was expressed in 6/85, but the variation was not detected by
the analysis. Alternatively, VlhA.3.09 could have been the predominant VlhA for both strains,
with K5234 populations generating a higher number of phase variants which expressed no VlhA
family member. If the two strains do in fact express different predominate VlhAs during the
initial stage of infection, the epitope of the VlhA expressed by K5234 could elicit a stronger
antibody response than VlhA.3.09, contributing to the enhanced infectivity of K5234. The
predominant VlhA of K5234 may also have enhanced functionality when compared to
VlhA3.09. VlhAs have been shown to mediate the attachment of M. gallisepticum to chicken
erythrocytes (Markham et al., 1992), and, recently, it was discovered that M. gallisepticum is
capable of invading erythrocytes and is commonly found in the bloodstream of infected chickens
(Vogl et al., 2008). It follows that enhanced VlhA functionality could aid both the dissemination
of the pathogen within the host and the evasion of the host‟s immune response. Regarding the
latter scenario, in which K5234 was predisposed to generate phase variants at a higher frequency
than 6/85, it has been demonstrated that VlhA phase variants can dominate the acute stages of
infection (Glew et al., 2000). VlhA phase variants could hide from the host‟s immune response
by not expressing any VlhA, replacing the function of VlhA with an alternative adhesin.
Alternatively, phase variants may be more suitable for colonization during early infection. VlhAs
are known to self-interact (Markham et al., 98), causing the clumping of cells which may
actually detract from the organism‟s ability to spread along a surface. If, indeed, the 3.7-fold
decrease in VlhA.3.09 reflects a higher abundance of phase variants in the K5234 experimental
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populations, it is also possible that the increased frequency of variants resulted from an unknown
regulatory activity rather than the predisposition of the organism. In lieu of the experimental
findings and previous research involving VlhA, variations in VlhA expression likely play a role
in the enhanced virulence and persistence of K5234 as compared that of 6/85.

Adhesins
Cytadherence is considered a prerequisite for the pathogenesis of many mollicutes, and
adhesins are often considered the primary virulence factors of these organisms (Rottom, 03).
After being inhaled, mollicute respiratory pathogens often adhere to the epithelial cells of the
host‟s respiratory tract (Bradbury, 05). Strong adherence prevents the immediate clearing of the
organism by the host‟s immune system, allowing the initiation of other colonization mechanisms,
such as motility, cell invasion, and biofilm formation. The best studied mollicute adherence
system is that of M. pneumoniae, which localizes adhesins at one end of the cell in what is called
a terminal tip organelle (or attachment organelle) (Rottom, 03). While the attachment of M.
gallisepticum is not as well elucidated as that of M. pneumoniae, M. gallisepticum does possess a
terminal tip organelle and has several adhesins which are homologous to those of M.
pneumoniae, two of which appeared in this study (Fig. 6, p. 58).
GapA, which increased 2.27-fold in K5234, has been implicated in M. gallisepticum
cytadherence and is, like VlhA, phase variable (Papazisi et al., 2003). The putative function of
GapA was determined by searching the genome of M. gallisepticum for homologues to the wellstudied adhesions of M. pneumoniae and M. genitalia, which belong to the same phylogenic
cluster as M. gallisepticum. A gene was located that shared 45% homology to the M. pneumonia
P1 adhesin and 46% homology to the M. genitalium MgPa adhesin, both of which are the
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primary adhesin in there respected organism (Goh et al., 1998). This putative adhesin gene was
located at the beginning of a multi-gene operon and was designated gapA (M. gallisepticum
adherence protein A). In tracheal ring attachment inhibition assays, labeling M. gallisepticum
cells with a GapA antagonist resulted in reduced attachment by 64% (Goh et al., 1998). Several
other assays, both in vitro and in vivo, have demonstrated that GapA is essential to M.
gallisepticum cytadherence (Papazise et al., 2000; Papazise, 2002 et al., Mudahi-Orenstein et al.,
2003).
In order for M. gallisepticum to attach to host cells and cause infection, gapA expression
must co-occur with the expression of crmA (Papazise et al., 2002). CrmA expression increased
3.88 fold in K5234. The function of crmA was determined, in part, by comparing the protein
expression profile of the avirulent, attenuated M. gallisepticum Rhigh strain with its virulent
progenitor, strain Rlow. Papazise et al. identified three proteins present in Rlow that were absent in
Rhigh. One of the absent proteins was GapA. The gene of another absent protein was located
immediately downstream from gapA and shared significant sequence homology to genes
encoding attachment accessory molecules in M. pneumoniae and M. genitalium. This putative
cytadherence gene was designated crmA (cytadherence related molecule) (Papazisi et al., 2000).
In cell culture attachment assays, attachment of the avirulent Rhigh strain was 75% less than that
of the virulent Rlow strain. Complimenting Rhigh with wild type gapA or crmA did not restore wild
type levels of attachment; however, complementing Rhigh with the entire Rlow gapA operon,
containing both gapA and crmA, did result in attachment and virulence phenotypes in vitro and in
vivo (Papazisi et al., 2002). Comparative sequence analysis of gapA and crmA indicates that they
might interact with each other in the cytoplasm, implying that not only co-expression but also
coordinated action between the two proteins may be necessary for attachment (Papazise et al.,
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2003). This is consistent with the functions of homologues in M. pneumoniae (Krause, 2001).
Transposon mutagenesis studies conducted by Orenstein and co-workers confirmed that GapA
and CrmA are essential to the cytadherence and virulence of Rlow. Of the 3,500 mutans screened,
only 5 had attachment and avirulent phenotypes. Two of these contained transposons in gapA
and one contained a transposon in crmA. (Mudahi-Orenstein et al., 2003).
GapA/CrmA expression is phase variable. Phase variants arise as a consequence of a
reversible nonsense mutation at the beginning of the gapA gene and not as a consequence of the
deletion or addition of intergenic trinucleotide repeats, as is the case for VlhA. The mechanism
by which the reversible nonsense mutation is achieved is unknown; it cannot be reconciled with
slipped-strand mispairing, the mechanism (not well understood itself) used to explain the DNA
replication error that promotes trinucleotide repeat mediated phase variation (Rosengarten et al.,
2000; Winner et al., 2003).
Together, this data demonstrates that GapA and CrmA are essential to the cytadherence
and virulence of M. gallisepticum Rlow. Cytadherence not only enables bacteria to avoid host
clearance, it is also a prerequisite for other physiological activities associated with mollicute
pathogenesis, like cellular invasion and motility (Much et al., 2002; Nakane et al., 2009).
Increased levels of GapA and CrmA in the virulent field strain (K5234) may have contributed to
its increased persistence, colonization, and virulence.

Energy metabolism and housekeeping enzymes
Many of the proteins in the data set provide basic metabolic functions. The role these
“housekeeping enzymes” might potentially play in pathogenicity is typically overlooked. But
“housekeeping genes may confer virulence” (Pollack, 2002). Hudson et al. note:
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Traditionally, the Lpd protein [dihydrolipoamide dehydrogenase of M. gallisepticum] would be
considered a metabolic factor, and therefore, its role in pathogenicity might never be
investigated…The definition of what constitutes a virulence-associated determinant is not limited
to toxins and cytadhesins, but also includes proteases, regulatory proteins, stress response
proteins, transport proteins, and proteins involved in metabolism. A virulence-associated
determinant is therefore defined as any factor that confers a selective advantage on the pathogen,
allowing it to colonize the host, persist, propagate, and cause disease (Hudson et al., 2006).

The relevance of housekeeping enzymes as virulence factors has been heightened by the
discovery that many housekeeping enzymes, including all five enzymes of the triose portion of
glycolysis, can localize on the cell surface of prokaryotes, with several capable of mediating the
attachment to host cell fibronectin and plasminogen (Pancholi and Chhatwal, 2003). While it is
difficult to reconcile most of the variations in abundance of metabolic enzymes in the current
study with known mechanisms of M. gallisepticum virulence, these proteins may have
contributed to the increased persistence and virulence of K5234, and thus they warrant
discussion.
The primary locus of fermentative mollicute metabolism is pyruvate. Mollicutes
are capable metabolizing pyruvate to lactate, acetyl-CoA, or oxaloacetate (Fig. 7, p. 59) (Hudson
et al., 06; Razin et al., 98). With the exception of one of the three components of the pyruvate
dehydrogenase complex (PDHC), the enzymes responsible for the conversions of pyruvate to
lactate and acetyl-CoA decreased in abundance in the virulent field strain (K5234) as compared
with the attenuated vaccine strain (6/85). These enzymes included lactate dehydrogenase (Mdh)
and two of the three enzymes of the PDHC, pyruvate dehydrogenase (AcoA) and
dihydrolipoamide acetyltransferase (AceF). The third PDHC enzyme, dihydrolipoamide
dehydrogenase (Lpd), showed increased levels in K5234.
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As mentioned in the introduction, fermentative mollicutes possess complete glycolytic
pathways but lack TCA cycles, cytochromes, and quinones and are thus incapable of generating
ATP by oxidative phosphorylation. Most of their ATP is thought to be produced by substratelevel phosphorylation during glycolysis (Pollock, 02). Glycolysis relies on the electron accepting
role of NAD+, which is reduced to NADH and must be regenerated in order for glycolysis to
continue. In mollicutes, the major pathway for regenerating NAD+ is the reduction of pyruvate
(the end product of glycolysis) to lactate, with the concomitant re-oxidation of NADH to NAD+
(Equation1). This conversion is catalyzed by lactate dehydrogenase (the Mdh protein in M.
gallisepticum), which decreased -1.85, -1.71, and -1.68 fold in the current study (Figure 3). The
malate dehydrogenase activity observed in some mollicutes is also attributed to lactate
dehydrogenase and will be discussed later (Pollock et al., 97).

Equation 1:

Pyruvate + NADH → Lactate + NAD+

It has been shown in several fermentative mollicutes that lactate dehydrogenase is deactivated by reduced levels of fructose1,6-bisphosphate (the final metabolite of the hexose
portion of glycolysis) and it is hypothesized that this feed forward inhibition shunts pyruvate
toward acetyl-CoA and/or oxaloacetate and away from lactate and the re-oxidation of NADH to
NAD+. The assumption is that under growth limiting conditions, where glycolytic activity is
being reduced due to limited substrate, cells are less reliant on the regeneration of NAD+ and
may benefit from having fewer resources invested in the lactate pathway (Pollock, 02). This also
may increase the viability of a dense cell populations by decreasing the amount of lactate
secreted into the environment, as lactate production is accompanied by the acidification of the
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cellular milieu, which has been shown to inhibit cell growth at high cell densities (Pollock et al.,
97).
In addition to lactate, mollicutes can also convert pyruvate to acetyl-CoA by the PDHC, a
ternary complex composed of dihydrolipoamide dehydrogenase, dihydrolipoamide
acetyltransferase, and pyruvate dehydrogenase (Equation 2). Dihydrolipoamide acetyltransferase
(-1.71/-1.64) and pyruvate dehydrogenase (-9.13/-4.13) showed reduced levels in K5234, while
dihydrolipoamide dehydrogenase (2.61/2.60) showed increased levels. Additional ATP can be
generated by substrate-level phosphorylation with the conversion of acetyl-CoA to acetate
(Equation 3) (Halbedel et al., 2007; Madigan et al., 2009). However, the ATP generated by this
pathway is not thought to contribute significantly to the total ATP pool. Acetate is an important
precursor for fatty acid synthesis in most mollicutes (Pollock et al., 97).

Equation 2:

Pyruvate + CoA + NAD+ → Acetyl-CoA + CO2 + NADH

Equation 3:

Acetyl-CoA + Pi → Acetyl-phosphate
Acetyl-phosphate + ADP → Acetate + ATP

Of the enzymes involved in pyruvate metabolism that are represented in the dataset,
dihydrolipoamide dehydrogenase is the only one that has been linked to virulence in M.
gallisepticum (Hudson et al, 06). The role of dihydrolipoamide dehydrogenase in the PDHC is to
re-set the redox state of the complex toward the end of the conversion of pyruvate to acetyl-CoA
so that the PDHC can continue to function (White, 2000). Hudson et al. identified
dihydrolipoamide dehydrogenase as a potential virulence determinant using signature sequence
mutagenesis (SSM), an in vivo technique which involves inoculating a single animal with a pool

47
of tagged transposon mutants. If a mutant is unrecoverable, then it is hypothesized to contain a
transposon in a gene essential for in vivo survival, and thus the gene product is identified as a
potential “virulence-associated determinant.” Of the 27 mutants inoculated into chickens, the
only one that was not recovered from the tissue tested contained a transposon in the
dihydrolipoamide dehydrogenase gene. When compared to the wild type strain (the virulent
Rlow), protein homogenates from the dihydrolipoamide dehydrogenase mutant showed decreased
PDHC activity in vitro. The mutant was also attenuated in vivo. The authors concluded that the
lack of functional dihydrolipoamide dehydrogenase rendered the PDHC inoperative after one
reaction, decreasing the amount of ATP that could potentially be produced by the conversion of
acetyl-CoA to acetate, causing a growth defect which was masked in vitro but manifest in vivo
(Hudson et al., 06). In a follow up study, the authors evaluated the SSM Lpd mutant as a vaccine
candidate. Under the experimental condition employed, the Lpd mutant outperformed the
vaccine strains ts-11 and F-strain (Gates et al., 2008). Recently, in Mycobacterium tuberculosis,
dihydrolipoamide dehydrogenase was shown to be a component of two enzyme complexes other
that the PDHC. Both enzyme complexes are colonization factors, one provides protection from
host born reactive nitrogen intermediates and the other prevents the accumulation toxic
intermediates of amino acid metabolism (Venugopal et al., 2011). These activities have not been
investigated in M. gallisepticum, but they may exist and may have contributed to the attenuation
of the Lpd mutant discussed above. Lastly, in a study which compared the transcriptomes of M.
gallisepticum cells grown in broth versus cells grown in association with eukaryotic cells,
dihydrolipoamide dehydrogenase was reported to be downregulated 2.28 fold in attached cells
(Cecchini et al., 07). Interestingly, lactate dehydrogenase (-3.50) and dihydrolipoamide
acetyltransferase (-2.22) were also shown to be downregulated. As previously mentioned, these
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two enzymes showed a decreased abundance in K5234. The downregulation of PDHC enzymes
and lactate dehydrogenase in the transcriptome study suggests a decreased dependence on the
conversion of pyruvate to lactate and acetyl-CoA in what is thought to be a more persistent
lifestyle.
In addition to lactate and acetyl-Co, the other major product of pyruvate metabolism in
mollicutes is oxaloacetate (OAA) (Equation 4). Oxaloacetate can be used as a substrate for
amino acid biosynthesis, or it can be converted to malate by the activity of lactate dehydrogenase
(Equation 5). As with the production of lactate, malate production is accompanied by the
regeneration of NAD+. It is thought that the malate pathway may provide organisms with a
means of producing NAD+ without the deleterious effects of the acid production associated with
the lactate pathway. In mollicutes, low malate dehydrogenase activity has been associated with a
decreased dependence on NAD+ regeneration and an increased flow of oxaloacetate to amino
acid biosynthesis (Pollock et al., 97; Pollock, 02).

Equation 4:

Pyruvate + ATP + CO2 → OAA + ADP + Pi

Equation 5:

OAA + NADH → Malate + NAD+

The evidence that some mollicutes funnel pyruvate away from lactate and malate under
growth limiting conditions, and that M. gallisepticum downregulates lactate dehydrogenase and
two of the three enzymes of the PDHC when grown in contact with eukaryotic cells suggests a
possible correlation between the increased persistence of K5234 in the field trials and the
decreased levels of lactate dehydrogenase and the PDHC enzymes observed in the current study.
One possible explanation is that K5234 is a more effective parasite, in that it may be able to
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acquire more metabolic precursors from its host and is thus less dependent on energy metabolism
producing the necessary ATP needed for macromolecular subunit biosynthesis. Another possible
scenario is that the decreases reflect a metabolic state that is more conducive to long term
persistence in a substrate limiting environment, and that K5234 achieves this state by either
investing fewer resources in pyruvate metabolism in general or by funneling pyruvate away from
lactate and acetate at the pyruvate locus, or both. If this were to be the case, then either K5234 is
simply genetically predisposed toward this state, or it is more effective at regulating metabolic
enzymes than is 6/85. In either case, the variation would have to have been masked in the
nutrient rich, in vitro growth media, where the two strains had similar growth curves, but become
apparent in the more competitive and limiting in vivo environment. If the variations involved
variable regulation, the obvious question is why this shift toward stationary phase growth
occurred in vitro during mid-exponential phase in K5234, and also why it occurred in K5234 and
not 6/85. It has been reported that variations in the expression of metabolic enzymes observed
during transitional phase cells of some bacteria actually begin in mid-exponential phase growth
(Cohen et al., 2006). Decreases in the abundance of FtsZ (-1.60), NrdA (-1.97), and NrdF (-2.84,
-1.95) in K5234 could also indicate preparation for slower growth. FtsZ (filamentous
temperature sensitive - Z) is a tubulin-like protein that initiates cell division by polymerizing into
a ring around the center of a growing cell (Madigan, et al., 2009). The decrease in abundance of
FtsZ could simply reflect a decrease dependence on FtsZ specifically for cell division, as the
protein was recently found to be nonessential to cell division in M gallisepticum’s close relative
M. genitalium (Lluch-Senar and Piol, 2010). Two subunits of ribonucleotide reductase (NrdA
and NrdF) showed a decreased abundance in K5234. Ribonucleotide reductase reduces
ribonucleotides to deoxyribonucleotides in preparation for chromosomal replication (Madigan et
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al., 2009). It is possible that by an unknown regulatory system K5234 begins preparing for
stationary phase growth before 6/85 does, and that this is not reflected in the growth curves of
the two strains, though it may manifest with prolonged, late stationary phase growth, which was
not included in the experimental growth curves. Perhaps the regulation of metabolism in K5234
is slightly different and more sensitive than that of 6/88. Also, in a substrate limiting
environment, K5234 may be less dependent upon fatty acid biosynthesis and benefit from having
fewer resources invested in the acetate pathway.
While no significant change in the abundance of the enzymes needed to convert
oxaloacetate to amino acids was detected by in this study, it is possible that K5234, when
compared with 6/85, funnels less pyruvate toward lactate and acetyl-CoA and more pyruvate
toward amino acids and protein biosynthesis, perhaps toward the synthesis of structural proteins
that are directly associated with persistence and virulence – like GapA, CrmA, and VlhA. It is of
interest that while lactate dehydrogenase and the PDHC enzymes were down-regulated in the
Cecchini et al. study, numerous ribosomal proteins were up-regulated, indicating a generalized
increase in translation (Cecchini et al., 2007). In the current study, FusA, a translation elongation
factor, increased in abundance in K5234. This, likewise, could indicate an increase in translation.

Other proteins of interest
The most conspicuous aspect of the results is the high fold change of AtpA (ATP
synthase alpha chain) and AtpD (ATP synthase beta chain); the former increased 3.76/3.09 and
the latter increased 19.57/11.19/6.02 in K5234. As previously mentioned, mollicutes are
incapable of generating ATP at the expense of the proton motive force, a process catalyzed by
ATPase. Mollicutes possess ATPase, but their ATPase acts only in reverse, using energy from
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ATP hydrolysis to establish ion gradients by pumping hydrogen or sodium ions out of the cell
membrane. In addition to their role in ATP synthesis, ion motive forces are also used to drive
cellular activities like membrane transport and motility (Pyrowolakis et al., 1998; White, 2000).
However, it has been demonstrated that the gliding motility exhibited by mollicutes is driven by
the direct hydrolysis of ATP (like Type IV pila mediated motility), as opposed to being driven by
ion motive forces (like flagella mediated motility) (Charon, 2005; Jaffe et al., 2004).
The ATPase of M. gallisepticum has the same eight subunits that compose the typical
bacterial F-type ATPase, with AtpA and AtpD composing the catalytic portion of the complex
(Rasmussen et al., 1992). However, the AtpA and AtpD that increased in abundance in this study
seem to be additional variants, possessing a PS00107 protein kinase motif, and their
chromosomal location is different than that of the other eight subunits (Gutman et al., 2005;
Papazisi et al., 2003). It is unclear, but perhaps M. gallisepticum has variable ATPases, some
containing conventional AtpA and AtpD subunits and others containing variant subunits. Due to
the high fold change of these two proteins and the importance of ATPases to cellular physiology,
further investigation into the function of these ATPase subunit variants is warranted.
Thioredoxin reductase (TrxB) increased 1.91 fold in K5234. Along with thioredoxin,
thioredoxin reductase is a component of the NADP+ / thioredoxin system (NTS). The NTS is
involved in numerous processes in eukaryotes, but little is known about its function in
prokaryotes. “Although the magnitude of the role of [the] thioredoxin-reductase system…in
mollicute metabolism is presently not certain, we imagine that it is significant,” writes one
researcher (Pollock, 2002). It has been reported that the mollicute NTS is capable of protecting
cells from the deleterious effects of reactive oxygen species (ROS) by transferring electrons from
NADPH (the origin of the NADPH is not known) to proteins and low molecular weight
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molecules (Fig. 8, p. 60), thereby maintaining them in their functional reduced forms and
protecting them from deleterious oxidation by host-born and native ROS - such as superoxide,
hydroxyl radicals, and H2O2, and organic peroxides (Ben-Menachem et al., 1997; Koharyova and
Kollarova, 2008; Pollack, 2002). Mollicute infection sites contain an abundance of ROS, mainly
H2O2. Hydrogen peroxide is considered a virulence factor of mycoplasmas and is also produced
by host phagocytes (Madigan 09 et al.; Jenkins et al., 2008). The NTS of other bacteria provides
protection from nitric oxide and reactive nitrogen species, and the thioredoxin reductase of
mycobacteria has been discussed as a potential drug target (Jaeger et al., 2006; Qu et al., 2009).
As mollicutes lack catalase and peroxidase activities (Pollock, 2002), NTS may be their primary
defense mechanism against ROS, and elevated levels of TrxB could enhance both colonization
and virulence.

Equation 6:

Trx-S2 + NADPH + H+ → Trx-(SH)2 + NADP+
↓
Protein-S2 + Trx-(SH)2 → protein-(SH)2 + Trx-S2

The presence of guanylate kinase (Gmk) in the data set is of interest because it is one of
the very few M. gallisepticum proteins that possesses motifs indicative of regulatory proteins.
Thus far, no conventional regulatory proteins have been described in M. gallisepticum (Papazisi
et al., 2003).

Hypothetical proteins
Six conserved or hypothetical proteins varied in abundance between the two strains. Two
of these proteins have been renamed since the initial sequencing of strain Rlow and the
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completion of the current study. MGA0674, which decreased 1.63-fold, is now named MslA, for
Mycoplasma-specific lipoprotein A, and MGA1203, which decreased 1.59-fold, is now named
Hlp2, for high molecular weight (HMW) 3-like protein (May et al., 2006; Szczepanek et al.,
2010b). MslA has appeared in two global transcript studies. In a transcriptomic comparison of
strain Rlow cells grown in broth versus cells grown in association with eukaryotic cells, MslA was
downregulated 2.5-fold, the same fold-change direction as in this study (Cecchini et al., 2007).
However, MslA transcripts were 6-fold more abundant in the virulent Rlow strain than the
attenuated F strain. Szczepanek and co-workers reported that MslA was immunogenic, and that
mutants with transposons in mslA had reduced recovery and attenuated virulence in vivo. The
role MslA plays in M. gallisepticum physiology and pathogenesis is yet to be determined
(Szczepanek et al., 2010b). Hlp2, which also decreased in abundance in K5234, is classified as a
cytadherence-related protein based on homology to the M. pneumonia protein HMW2 (May et
al., 2006). HMW2 is a major component of the M. pneumonia’s terminal tip structure and is
involved in the localization of numerous proteins that mediate not only attachment and gliding
motility but also cell division (Bose et al., 2009; Hasselbring et al., 2006). Hlp2 is also
homologous to MG218 of M. genitalium. Like HMW2, MG218 is a terminal tip protein essential
to attachment and motility (Pich et al. 2008). Along with MslA, the expression MGA267 and
MGA573 were reported to vary in the Cecchini et al. study. MGA267 showed an increase in
abundance in the K5234 and was also upregulated in cells grown in contact with eukaryotic cells,
while MGA573 increased in abundance in K5234 but was downregulated in cells grown in
contact with eukaryotic cells (Cecchini et al., 2007). The appearance of hypothetical proteins in
the data set demonstrates that these proteins are expressed and presumedly functional in the two
strains studied. Thirty-three percent of the M. gallisepticum predicted proteome is comprised of
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hypothetical proteins. Functional analysis of these proteins will be essential to a comprehensive
understanding of M. gallisepticum physiology. As demonstrated by the previous discussion,
comparative functional genomics is a powerful tool and could play an important role in the
investigation of proteins with no known function.

Conclusion
Using 2DE-MS based comparative expression proteomics, numerous variations between
the proteomes of two genetically similar M. gallisepticum strains were uncovered. Strain K5234
was isolated from a flock of poultry that had been vaccinated with the live attenuated vaccine
strain 6/85. Field trials demonstrated that K5234 was virulent, and that it persisted longer in birds
than did 6/85. However, the two strains were indistinguishable using accepted methods of
mycoplasmal differentiation (RAPD and selected sequence comparison). The nature of the
phenotypic variations (increased virulence and persistence) observed during the field trials was
investigated in vitro using 2DE-MS based proteomics. Highlights of the data set include an
increased abundance in K5234 of several phase and/or antigenic variable virulence factors (to
date, the only three well investigated virulence factors of M. gallisepticum), and a decreased
abundance in K5234 of enzymes involved with pyruvate metabolism. These and other proteins in
the data set could play a role in the increased virulence and persistence of K5234. They may also
be involved with phenotypic variations between K5234 and 6/85 that have not been detected.
This study demonstrates the utility of quantitative comparative proteomics as a tool to
investigate the molecular mechanisms behind phenomena. Regarding M. gallisepticum,
mechanistic data could aid both the understanding of virulence at a basic level and the discovery
or development of enhanced vaccine strains. As mentioned in the introduction, complications
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due to M. gallisepticum infections are an enormous economic burden to the poultry industry
(Papazisi et al., 2003). Currently, live-attenuated vaccines are the most promising options for
control. Bacterins have proved ineffective. Antibiotics can control symptoms but cannot clear
infections. Biosecurity measures are effective against sporadic outbreaks when flock eradication
is an option. But in the egg laying industry, due to its structure and extreme size, eradication is
not an option. Flocks can become infected for life, and live-attenuated vaccines are currently the
best option for control (Evan et al., 2005; Gates 2008). But, as acknowledged by Jeff Evan of the
USDA poultry research team, vaccine development is hindered by a lack of mechanistic
knowledge concerning vaccine and field strains (the molecular studies cited in the discussion
employed almost exclusively laboratory strains); what is known about field and vaccine strains is
mostly phenomenological. For example, regarding the three vaccine strains currently in use, the
F strain is an effective colonizer, persist well, and is capable of displacing virulent field strains,
but induces mild respiratory disease and is transmissible to flocks where it is a pathogen. In
contrast, strains ts-11 and 6/85 are safer and less transmissible but do not persist well and are less
protective (Abd-El-Motelib and Kleven, 1993). With few exceptions, the mechanisms which
account for these observations have not been investigated. If the superior protection provided by
F-strain results from competitive exclusion, then what mechanisms account for its ability to outcolonize field strains and why can it achieve this exclusion better than stains ts-11 and 6/85? If
F-strain‟s superior protection is the result of eliciting an immune response that displaces
pathogens more effectively than the immune response elicited by ts-11 and 6/85, then how is this
achieved? The current study is an initial (or pilot) experiment conceived to address these
questions. The data generated will be used as a starting point for directed physiological and
molecular experiments, hopefully resulting in a more thorough understanding of the nature of
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what is desirable and undesirable in a vaccine strain. This knowledge will then be used to
identify markers and develop assays with which to screen vaccine candidates or, alternatively,
used as a basis for the development of recombinant vaccines.
Additionally, the potential demonstrated by this study to elucidate mechanisms of M.
gallisepticum pathogenicity has encouraged the initiation of a long-term, large-scale research
effort of which proteomics is the core approach. Currently, a LC-based proteomic comparison of
K5234 and 6/85 is being carried out - which, along with the differential data generated by this
study, will be used as a starting point for a large-scale systems (or modeling) project. The
vaccine strains ts-11 and F-stain, the sequenced Rlow laboratory strain, and various field strains
will be incorporated into this project. The conditions under which the proteomic comparisons
will be carried out will have to be standardized. However, comparative proteomics lacks the
rigor of genomic and transcriptomic approaches. As mentioned in the introduction, the lack of
rigor stems both from the technology and the dynamic nature of protein pools within a cell. The
development of systems models for an organism that is inherently variable using technology that
is inherently variable will undoubtedly be challenging and will likely require a consensus
approach.
As one reviewer notes, “It is no coincidence that the first vaccines were developed
against pathogens with little variability” (Telford, 2008). The complications involved with
developing live-attenuated vaccines for the control of highly plastic pathogens are extensive, but
a more thorough understanding of pathogenic mechanisms via global proteomic approaches will
likely help address these complications. Proteomics also has the capacity to help elucidate the illunderstood genetic mechanisms that govern the replication errors that lead to phase and antigenic
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variations (and the repair mechanism that overlook these errors) and also perhaps implicate
environmentally responsive regulatory networks in the process.
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Fig. 6. Cytadherent M. gallisepticum. M. gallisepticum cells attached via attachment organelle
to chick embryo epithelium 2 days post-infection (Bradbury, 2005).
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Fig. 7. Pyruvate catabolism in mollicutes. This figure shows the experimental abundance
changes in enzymes involved with pyruvate metabolism in the virulent K5234. Negative fold
changes (∆) indicates decreased levels in the virulent K52 strain in versus the 6/85 vaccine strain.
Abbreviations: Mdh (lactate dehydrogenase), LDH (lactate dehydrogenase), PDHC (pyruvate
dehydrogenase complex), AcoA (pyruvate dehydrogenase), Lpd (dihydrolipoamide
dehydrogenase), AceF (dihydrolipoamide acetyltransferase).
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Fig. 8. NADP+ / thioredoxin system (NTS).
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APPENDIX
DEATILED LABORATORY PROTOCOLS

Crude protein extract
Lyses buffer (30 mM Tris, 7 M urea, 2 M thiourea, 4% CHAPS) – 15 ml
____make 25 ml 8 M urea, 2.3 M thiourea
____12 ml ddH20
____12 g urea
____4.5 g thiourea
____make up to 25 ml with ddH2O
____add 250 mg amberlite and stir for 1 h
____filter into clean, rinsed bottle
____13.2 ml deionized urea/thiourea solution
____450 ul 1 M Tris
____150 ul nuclease mix
____300 ul protease inhibitor
____600 mg CHAPS
____pH to 8.6 with HCL
____make up to 15 ml
____950 ul aliquots and store at -70ºC
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Protocol
1) Remove cell pellets and lysis buffer (LB) from -70ºC. Place pellets in -20ºC and allow
LB to thaw at room temp.
2) Vortex LB thoroughly. Making sure all presipitated dissolves. Add required volume to
pellet. Incubate at room temp for 2 min.
3) Disperse pellet by vortexing (and pipeting if needed).
4) Transfer slurry to sonication vessel incubate on ice for 10 min while:
5) Clean sonication tip with 3 rounds of ethanol and water.
6) On ice, sonicate sample 6 x 15 s on 15 s off.
7) Transfer lysate to microfuge tube and place on ice.
8) Repeat steps 1-7 for remaining samples.
9) Allow all samples to incubate at room temp for 1 hr.
10) Transfer lysates to 1.5ml thick-walled centrifuge tubes and centrifuge 40K x g at 7ºC for
1 hr.
11) Transfer clarified lysate to tube on ice.
12) Aliquot 70 ul into screw-cap tubes and store at -70ºC.

IPG strip rehydration with reswelling tray
1) Using toothbrush, clean reswelling tray with IPG detergent (or other non-ionic detergent).
Rinse thoroughly with ddH20 and airdry (if needed, use crewipes to dry).
2) Remove appropriate amount of Destreak rehydration solution from -20ºC. Bottle contains
3ml of solution. 450 ul required per well. Once thawed, vortex vigorously until white
solid (urea) dissolves.
3) Add IPG buffer (or other ampholytes) to 0.5% v/v (15ul to 3ml, 60ul to 6ml).
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Note: Ampholyte range should match that of the strip. However, many prefer 3-11NL
ampholytes when using 3-7NL or 4-7 strips.
4) For right –handed persons, orient the reswelling tray so that the acidic (+) end is to the
left. Acidic end has the little circular well. Pipet 450 ul of rehydration solution into the
appropriate number of wells.
Note: Many find that applying rehydration solution toward cathodic (-) end of well
results in more complete rehydration.
5) Load strips. Remove strips one at a time and load. Grasp acidic end (the one with the bar
code) between thumb and index finger of left hand so that the protective cover in facing
away from left hand. With right hand, gently peel off protective cover. Again with right
hand, grasp basic end backing between thumb and index finger so that when the strip is
flipped, the gel side is facing down and the plastic backing is up. Lower the strip so that
acidic end contacts pool of rehydration buffer. Gently slide the strip back and forth across
the solution, making sure that gel is wet before contacting any part of tray that is dry.
Lower and release basic end so that acid end completely crosses well at acidic end.
6) Cover each strip with 3.4 ml of Drystrip cover fluid (mineral oil).
7) Insert cover, gently move tray to place of incubation, and balance with black nobs.
8) Incubate strips for 20-30 h at room temp.

Reconstitution of CyDyes
1) Transfer small volume of DMF to microfuge tube.
Note: Once cracked, DMF reagent should only be used for 3 months. After 3 months,
crack another one.
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2) Remove un-opened dye from -20ºC. Leave dye in black plastic container. Incubate on
ice for 5 min.
3) Add appropriate volume of DMF: 5 ul to 5mM, 10 ul to 10mM, and 25 ul to 25 mM. This
gives a stock solution of 1mM.
4) Vortex dye for 30 s.
5) Spin down.
6) Immediately return dye to -20ºC.
Note: Reconstituted dye is stable for up to 2 months or up to the expiration date.

Minimal Cy dye labeling
1) Dilute samples to 5 ug/ul (5mg/ml) with lysis buffer (LB) in a total volume of 75 ul. The
LB is the diluent. This will be enough for analytical gels, several preparative gels, and a
small amount to archive. To determine appropriate volume of sample and LB, divide
375ug by the concentration of the sample in ug/ul (75 ul of a 5 ug/ul solution contains
375ug). Enter the result (ul) into the chart. The left-hand blank. The one for sample.
Subtract the result from 75 ul. Enter this result in the right-hand blank. The one for
diluent. Label microfuge tubes according to following chart. Dilute samples. Vortex
diluted samples and place on ice.
sample A (cy3 control)____

sample B (cy5 variant)____

1A._____ul sample _____ul diluent 1B._____ul sample _____ul diluent
2A._____ul sample _____ul diluent 2B._____ul sample _____ul diluent
3A._____ul sample _____ul diluent 3B._____ul sample _____ul diluent
sample B (cy3 variant)____

sample A (cy5 control)____

4B._____ul sample _____ul diluent 4A._____ul sample _____ul diluent
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5B._____ul sample _____ul diluent 5A._____ul sample _____ul diluent
6B._____ul sample _____ul diluent 6A._____ul sample _____ul diluent
2) Transfer 55 ul of each diluted sample to single tube labeled pool. Vortex pooled sample
and place on ice.
3) Multiply number of analytical gels plus one by 10 ul (6 + 1 = 7, 7 x 10 ul = 70 ul).
Transfer this amount of pooled sample to tube labeled standard. This will be enough
standard for each analytical gel and a little left over. Vortex standard sample and place on
ice. The remaining pooled sample will be used for preparative loads and archiving.
4) Transfer 10 ul of remaining diluted sample to reaction tube (simply another microfuge
tube) labeled identically to dilution tube. Place reaction tubes on ice.
5) Prepare CyDye working solution (400 pm/ul). Remove dyes from -20ºC and thaw on ice
for 5 min. Keep dye tube in black plastic container. Vortex thawed dyes and spin down.
Transfer small amount of DMF to tube labeled DMF. According to the following chart,
transfer appropriate volume of DMF to tubes labeled Cy2, Cy3, and Cy5. Add the
appropriate volume of thawed dye respected tube. Return stock dyes to -20ºC
immediately. Vortex diluted dye, spin down, and place on ice in the dark.
4 samples: add 2 ul stock to 3ul DMF
6 samples: add 3 ul stock to 4.5ul DMF
8 samples: add 3.5 ul stock to 5.25ul DMF
6) Reaction. Working methodically, add 1ul Cy3 to Cy3 reaction tubes. Vortex each for 10
s, spin down, and return to ice. Add 1ul Cy5 to Cy5 sample tubes. Vortex each for 10 s,
spin down, and return to ice. Add 1 ul Cy2 per 10 ul standard sample to standard reaction
tube. Vortex, spin, and return to ice.
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7) Incubate reaction tubes for 30 min on ice protected from light. Place 10 mM lysine on
ice.
8) Quench reaction. Add 1 ul 10 mM lysine to Cy3 and Cy5 reaction tubes. Add same
volume of 10 mM lysine to standard reaction tube that was used for Cy2 in step 6. Vortex
and spin down each sample before return to ice protected from light.
9) Incubate reaction tubes for 10 min.
10) Proceed to reduction and 1st dimension or store samples at -70ºC.

Reduction and 1st dimension
1) Remove aliquot of 2X solubilization buffer (2XSB), aliquot of rehydration buffer (RB),
CyDye labeled samples, and pooled sample from -70ºC. Once thawed, vortex each.
Ensure precipitates are dissolved. Spin down labeled samples.
2) For each sample set, marry Cy3 and Cy5 samples by transferring entire contents of Cy5
tubes to Cy3 tubes.
3) Add 12 ul standard sample to each Cy3 tube. Now each Cy3 tube should contain 36 ul.
4) Add 36 ul 2XSB to each sample and vortex.
5) Transfer amount of pooled sample needed for preparative gels to fresh tube. Add equal
volume of 2XSB and vortex.
6) Incubate samples on ice in the dark for 30 min while:
7) Using treezers, gasp the strip‟s basic end backing. Lift, flip, and place in ceramic boat so
that acidic end (the one with the + and barcode) is pointed toward end of boat and
cathodic end of gel is at square end of boat. Make sure gel surface is up.
8) Cover each rehydrated strip with 4.4 ml Drystrip cover fluid (mineral oil).
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9) Place electrode pads moistened with 150 ul ddH20 on cathodic and acidic end on gel, not
the gel backing.
10) Place electrodes on electrode pads, several mm from the ends of the gel. Ensure that the
electrode is over the gel, not the gel backing.
11) Place sample cup several mm from the acidic end electrode pad. Ensure that the cut feet
contact the bottom of the boat and that they do not contact the boat‟s guides. Observe at
eyes level to make sure.
12) Fill each sample cup with 100 ul of Drystrip cover fluid. Allow gels to sit for 10 min
while:
13) Add 28 ul RB to each reduced sample (total volume now 100ul).Brig preparative sample
up to 100 ul with RB. Vortex each and spin down.
14) Ensure that cups are not leaking by making sure that level of Drystrip cover fluid in each
cup has not dropped.
15) Add entire sample contents (100 ul) to sample cup.
16) Place strips on IEF platform. Ensure that boat electrodes contact platform electrodes (the
gold part).
17) Place covers over boats and close hood.
18) Toggle to or program desired protocol, press start, enter the number of gels, and press
start again.
19) Protect unit from light.
20) Return remaining pooled sample to -70ºC.
21) After run completed, store strips in capped plastic tubes or proceed directly to strip
equilibration and 2nd dimension.
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Casting analytical and preparative gels
1) Prepare bind silane solution. The plates with vinyl spacers will be the back plates of
sandwiches. Gels are bound to the back plates. 4ml bind solution needed per back plate.
Bind–silane working solution (prepare fresh) – 10ml (enough for 2 back plates)
____8 ml 200 proof ethanol
____1.8 ml ddH2O
____200 ul glacial acetic acid
____12.5 ul bind-silane (this is 2X recommended amount)
2) Treat plates. Plates should have been cleaned and then treated with 1% HCL. Plates
should be dry and free of dust. Place plates on crewipes so that vinyl spacers are up. This
will be the inside of the gel sandwich. Pipet 4 ml of bind solution onto plates. Thoroughly
spread solution over plates with crewipe (or other lint-free wipe). Work up and down
across plates and across plates up and down. Cover plates with crewipes to protect from
dust. Allow plates to sit for 45 min while:
3) Prepare gels solution. Leave out APS. Measure larger volumes with 100ml graduated
cylinder.
Gel solution (12.5%) – 940 ml
____294 ml 40% monomer solution
____235 ml 1.5M TrisCl pH8.8
____392 ml ddH2O
____9.4 ml 10% SDS
____376 ul TEMED (80% of recommended amount)
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4) Prepare displacing solution.
Displacing solution (0.375 M TrisCl pH 8.8, 50% glycerol, 0.002% bromophenol blue) –
120ml
____20 ml ddH20
____30 ml 1.5M TrisCl, pH 8.8
____70 ml glycerol
____240ul 1% bromophenol blue
5) Prepare 10% APS by adding 1 g of APS to 9.6 ml ddH2O.
6) After 45 min (step 2), place reference markers on plates. Place reference markers 10.5 cm
up from plate bottoms (vinyl spacers go all the way to the edge at the bottom of the
plates) and slightly inward (several mm) of the vinyl spacers. Use tweezers to place
markers and press marker hard to plates. Allow plates to sit for additional 45 min before
loading the caster.
7) Grease gasket on removable front face of caster.
8) Load caster. Work briskly. Place plastic separator sheet to back of caster. Then back plate
(one with spacers). Then front plate. Then thin separator sheet, etc. Ensure all plates are
flush to one side of caster and all plate bottoms are flush and seated on caster bottom.
When all plates are loaded, fill any space between last plate and front of caster with thin
or thick separator sheets so that final sheet is flush with the front of the caster.
9) Secure front face of the caster.
10) Level caster.
11) Secure funnel tube stem in displacing solution reservoir.
12) Fill reservoir with 85 ml displacing solution.
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13) Add 9.4 ml 10% APS to gel solution and gently mix.
14) Pour gel solution until level with mark 3 cm from top of front plates and stop flow.
15) Remove funnel stem.
16) Adjust solution level by adding needed amount of remaining displacing solution to
reservoir.
17) Overlay gels with 2 ml water-saturated butanol.
18) Allow gels to sit for at least 1.5 h.
19) Place caster in large autoclave bucket and dismantle from plate.
20) Remove plates. Rinse plate with ddH2O. Rinse top of gel sandwiches, making sure water
saturated butanol is displaced. Trim off excess polymer.
21) Lay plate on seal wrap. Fill top gel gaps with storage buffer. Pipet storage buffer along
the gel sandwich bottoms. Wrap sandwiches.
22) Store overnight at room temperature.
23) If 2nd dimesion not started day after casting, gels can be stored for several days at 4ºC.

Equilibration and 2nd dimesion
1) Remove equilibration buffer (EB) from -4ºC. 1 tube (50 ml) per gel.
2) Split EB between 2 flasks. Add 0.5% DTT to one and 4.5% iodoacetamide to the other.
______ml EB x 0.005 = ______g DTT
x 0.045 = ______g iodo
3) Stir flask while:
4) Turn on heating block. Insert required aliquots (1 per gel) of agarose sealing solution.
5) Dilute electrophoresis buffer and pre-chill if desired.
6) Remove strip tubes from -70Cº. Incubate at room temp for 10 min in dark
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7) Add 20 ml DTT EB to gel tubes. Cap tubes and place on shaker at 80rpm. Incubate
15min in dark while:
8) Rinse gel sandwiches with ddH2O. Invert sandwiches and place in plate rack while:
9) Pour off DTT EB.
10) Add 20 ml ioda EB to gel tubes. Cap and shake as before. Incubate 10min in dark
11) Drain EB.
12) Fill 100 ml cylinder with 1X electrophoresis buffer.
13) With clean forcepts remove strip from tube and rinse in 100 ml cylinder containg
electrophoresis buffer.
14) Lay strip on ledge at top of sandwich gel with the acidic end to the left.
15) Use clean rule to position IEF strip on top of 2nd dimension gel. Make sure ruler only
contacts IEF strip gel backing.
16) Cover IEF strip with 1ml agarose sealing solution.
17) Incubate sandwiches for 5 min to allow sealing solution to solidify while:
18) Set tank to circulate. Add electrophoresis buffer to gel tank.
19) Insert appropriate number of gel blanks.
20) Ensure agarose sealing solution is solid.
21) Insert sandwiches into gel tank.
22) Program desire protocol and start.
23) After run, remove and rinse gel sandwiches with ddH2O.
24) Remove front plate from preparative gels. Place gels in fixing solution and store in dark.
25) Wrap analytical gels in seal wrap. Protect from light. Scan immediately.

80
Deep Purple Staining
Solutions
Fixing solution (7.5% acetic acid / 10% methanol) – 1 L
____825 ml ddH2O
____75 ml glacial acetic acid
____100 ml methanol
Wash solution (35 mM NaHCO3 / 300 mM Na2CO3) – 1 L
____750 ml ddH2O
____2.94 g NaHCO3
____31.8 g Na2CO3
____make up to 1 L
____verify pH 10 – 11 (solution can be stored up to 2 weeks)
Working stain solution – 500 ml/gel – 500 ml
____remove stain from -20ºC and incubate at room temp for 2 min
____shake concentrate briefly and transfer 2.5 ml to 500 ml ddH2O
Stabilization solution (7.5% acetic acid) – 3 L
____2775 ml ddH20
____225 ml glacial acetic acid

Protocol
1) Thoroughly clean and rinse (ddH2O) staining containers.
2) Prepare fixing solution.
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3) Remove gels from electrophoresis tank. Remove top plate. Place gels in 1 L of fixing
solution and incubate overnight.
4) Remove gel, rinse container and wash gel in 1 L wash solution for 30 min at 25 rpm.
5) Remove gel, rinse container and incubate in 1 L ddH2O for 5min at 25 rpm.
6) While gel is incubating in water, make working stain solution.
7) Remove gel, rinse container and cover each gel with 500 ml working solution. Incubate
for 1 h with gentle agitation (40 rpm) protected from light.
8) Remove gel, rinse container, and place gel in 1 L stabilization solution with gentle
agitation protected from light for at least 20 min.
9) Repeat step 8 twice (optional).
10) Scan gel using the green laser (532nm) and emission filter 560LP (PMT voltage will have
to be adjusted according to the protein load if saturation is an issue. Start with 550. Do
not go above 600). Or gels can be stored at 4ºC, between glass plates, in the dark, in
stabilization solution or 0.75% acetic acid.

Sypro Ruby staining
Solutions
Fixing solution (7.5% acetic acid / 10% methanol) – 1 L
____825 ml ddH2O
____75 ml acetic acid
____100 ml methanol
Stabilization solution (7.5% acetic acid) – 3L
____2775 ml ddH20
____225 ml glacial acetic acid
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Protocol
1) Thoroughly clean and rinse (ddH2O) staining containers.
2) Remove gels from electrophoresis tank. Remove front plate. Place gels in 1 L of fixing
solution and incubate overnight.
3) Remove gel, pour out fixing solution, rinse container, then fill with 400 ml Sypro Ruby,
and insert gel. Incubate with gentle shaking (50rpm) overnight protected from light.
4) Wash gels 6 x 20 min with 1.2L ddH20 with shaking at 25 rpm protected from light.
Rinse container between each wash. Alternatively, transfer gel from stain to 100%
methanol for exactly 1.00000 min (use stop watch). Wash gel with ddH20 and scan.
5) Scan gel with Sypro Ruby emission filter.
6) Replace front glass and store in stabilization solution.

Scanning analytical gels
1) Remove gels from tank, rinse with ddH2O, and wrap with sealwrap.
2) Wrap all seal wrapped gels in foil to protect from light and place at -4ºC.
3) Remove 1 gel. Rinse with ddH2O, Dry with crewipe while:
4) Using crewipe, clean scanner window with 2 rounds of 100% ethanol followed by
ddH2O.
5) Place position bar on window on edge closest to user.
6) Ensure that window is completely dry and position gel. Orient gel so that the top plate is
up and ledge is left. Position acidic side of gel on metal tabs of positioning bar.
7) Grasp basic side of gel with small positoning bar and lower gel. Close scanner hood.
8) Open Scanner Control.
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9) Set Acquisition Mode to Fluorescence.
10) Click Setup
11) On Typhoon Scanner Control under column Use de-select image 2, 3, and 4.
12) Set Emission filter to 520 BP 40 CY2, Blue FAM.
13) Ensure Laser is Blue2 (488) and Sensitivity is Normal.
14) Set PMT voltage to 550.
15) Under Auto Link Mode select Sensitivity.
16) Select OK.
17) On Typhoon Scanner Control tick Press Sample.
18) Set Pixel size to 1000 microns.
19) Select SCAN.
20) On Multiple Sample Naming screen select SCAN
21) Watch real time display of scan.
-

If red spots appear on gel return to Fluorescent Setup for Typhoon9410
screen. Reduce PMT voltage by 10 units (to 540) and repeat pre-scan. Repeat
until no red spots. Subract 10 units from the final PMT voltage that produces no
red spots. This will be the PMT voltage for Cy2.

-

If no red spots appear on gel, increase PMT voltage by 10 units (560) and scan.
Repeat until 1 or 2 red spots appear. Subtract 15 units from this voltage. This
will be the voltage for Cy2.

22) Repeat steps 10-21 for Cy3 and Cy5.
23) Go to Fluorescent Setup for Typhoon 9410 screen. Under Use select Image 1, 2, and 3.
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24) Set image 1 to 520 BP 40 CY2, Blue FAM. Set image 2 to 580 BP 30 Cy3, TAMRA,
AlexaFlour 546. Set image 3 to 670 BP 30 Cy5.
25) Enter respected voltages under PMT.
26) Ensure Laser for image 1 is Blue2 (488), for image 2 is Green (532), and for image 3 is
Red (633).
27) Sensitivity for all should be normal.
28) Ensure Auto Link Mode is Sensitivity.
29) Select OK.
30) On Typhoon Scanner Control window, under Tray, select DIGE Ettan Dalt and
number 1.
31) Under options, tick Press Sample. Set Pixel size to 100 microns. Set Focal Plane to +3
mm.
32) Tick DIGE File Naming Format and select SCAN.
33) On Multiple Sample Naming screen in Use Common Settings for All samples box on
line Folder, Browse to desired folder for data output and select Set.
34) On line Base File Name, enter the experiment name and the gel being scanned and select
SCAN
35) After scan complete open ImageQuant software. Under Tools, select Define area of
Interest. Outline desired area of interest.
36) Under File, select Save Gel Files from Dataset to Folder.
37) Select desired folder and Save.
.tiff or .gel files and can now be opened with DeCyder.
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Scanning preparative gels
1) Using crewipe, clean scanner window with 3 rounds of 100% ethanol followed by
ddH2O.
2) Place clean and dust-free top plate on gel adhered to back plate. Lower at an angle to
prevent trapping air.
3) Allow gel sandwich to sit for 5 min.
4) Remove gel sandwich from stabilization solution. Rinse with ddH2O. Dry with crewipe.
5) Position gel on window as per steps 5-7 of Scanning analytical gels.
6) Optimize PMT voltage as per steps 14-21 of Scanning analytical gels.
7) Scan gel as per step analytical gels, using the manufacturer‟s recommended parameters.
8) Store gel sandwich in stabilization solution at 4ºC.

Decyder differential analysis (overview)
1) Open Decyder module DIA / Create file for .gel file of analytical gel / Process gel image
(establishes spot boundaries) / filter / Save as .dia file and export as .xml file / repeat for
remaining analytical gels
2) Open Decyder module BVA / Import .xml files of all analytical gels / Assign gel
functions / establish experimental groups / In Match Table screen, merge spots and
landmark / Match / Run student‟s T-test / Filter data / Confirm results
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Plate cleaning and hydrolysis of residual bind silane
1) Dissemble gel sandwich. Place top plate aside in plate rack. Use plastic wedge to remove
bulk polymer from back plate. Work up and down and across plate.
2) Soak back plate in 1% Contrad for 2 h.
3) Scrape plate as per step 1. Rinse plate thoroughly to remove non-adhered polymer. Using
plastic wool, scrub plate thoroughly, rinse again, and dry with crewipe.
4) Inspect plate for residual polymer. Repeat step 3 until all polymer is removed.
5) Soak plates in 1% HCL for 2 h.
6) Rinse plates thoroughly with ddH2O.
7) Place plates in plate rack and set aside to dry. Put plate rack in autoclave bag labeled. Do
Not Autoclave.

Spot picking
1) Remove gel tray from spot picker and rinse with ddH20.
2) Cover the surface of the tray with ddH2O (just enough to cover bottom of tray).
3) Remove gel from 4ºC. Gently remove top plate. Orient try so that corner feet are toward
user. Place plate in tray, oriented so that bottom of gel is toward user. Secure gel. Making
sure both reference markers are between white lines of tray. Place tray with gel in picker.
Bottom corner feet fit on knobs toward user. Make sure all 4 feet are fit onto knobs.
4) Rinse 96-well plate with ddH2O. Place in bottom left (A) plate position. Situate down
and to the left.
5) Remove camera cover.
6) Close cabinet.
7) Place feed tube in bottle of ddH2O.

87
8) Open Ettan Spot Picker.
9) Click Tools then Prime Syringe. Enter 20 then click Prime.
10) Set Z-height.
11) Bottom right screen, click Load Pick List and open text file pick list.
12) Click Skip in Scanner Correction box.
13) After spots appear, click Next at bottom right. Read message and click Next again.
14) Click Auto Detection in Detect Marker box.
15) When marker detection complete, click next and enter output directory file name and
route. Then click Create Directory.
16) Click Run batch.
17) When picking complete, confirm plugs in each well by removing ddH2O and inspecting
well. Alternatively, scan 96-well plate with Deep Purple protocol. The gel can also be rescanned.
18) Replace cap on camera. Remove gel try. Remove gel from tray. Rinse tray and leave
inverted to dry.

Protein digestion
Reagent prep (20 samples)
50mM ammonia bicarb / 50% acetonitrile – 8 ml
____4 ml ddH2O
____4 ml acetonitrile
____31 mg ammonium bicarb
75% acetonitrile – 4 ml
____3 ml acetonitrile
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____1 ml ddH2O
20 ug/ml trypsin / 20 mM ammonium bicarb – 1 ml
____ to 10 ml ddH2O, add 16 mg ammonium bicarbonate (20 mM)
____add 1 ml 20 mM ammonium bicarbonate to trypsin vial (20 ug)
____mix and transfer to tube
50% acetonitrile / 0.1% TFA – 4 ml
____2 ml ddH2O
____2 ml acetonitrile
____4 ul TFA

Protocol
1) Prepare first 3 reagents…keep reconstituted trypsin at 4ºC.
2) Remove ddH2O, making sure not to smash or loose the plugs.
3) Add 100 ul 50mM ammonium bicarbonate/50% acetonitrile / incubate 20 min / remove
solution.
4) Repeat.
5) Add 100 ul 75% acetonitrile / incubate 20 min / remove solution.
6) Dry plugs in speed vac (may need to remove rotor) for 30 min with no heat.
7) Add 7 ul 20 ug/ml trypsin directly to each plug.
8) Seal plate and incubate at 37ºC overnight.
9) Make up last reagent.
10) Add 60 ul 50% acetonitrile/0.1% TFA / incubate 20 min / transfer to fresh tube.
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11) Add 40 ul 50% acetonitrile/0.1% TFA to each well / incubate for 20 min / marry to
previous 60 ul.
12) Dry solution in speedvac (no heat) until dry…around 2 h.
13) Proceed to ziptip or freeze samples at -20ºC.

Target plate cleaning
1) Cover plate surface with target plate cleaning solution.
2) Scrub surface with toothbrush.
3) Rinse scrubbed plate with ddH2O.
4) Dry plate with crewipe.
5) Dab very small amount of Pol metal cleaning polish on fresh crewipe.
6) Polish plate with crewipes in circular motion until no black residue is seen on the
crewipes (do not let polish dry).
7) Rinse plate with isopropanol and allow to air dry.

De-salting (uC18) for MS
Wetting solution (50% ACN in milli-Q water) – 1 ml
____500 ul ddH2O
____500 ul ACN
0.1% TFA in milli-Q water – 1 ml
____1 ml ddH20
____1 ul TFA
Elution solution (0.1% TFA / 70 % ACN in milli-Q water) – 1 ml
____700 ul ACN
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____300 ul ddH2O
____1 ul TFA

Protocol
1) Add 1.5 ul neat formic acid and vortex.
2) Add 8.5 ul 0.1% TFA, vortex, and spin down.
3) At max volume setting (10 ul) aspirate and discard wetting solution twice.
4) Equilibrate by aspirating and discarding 0.1% TFA 10X.
5) Bind by aspirating and dispensing sample 7X.
6) Wash bound sample 10X with 0.1% TFA.
7) Aspirate and elute 0.7 ul elution solution 5X (no air) and spot sample directly onto
TOF/TOF plate.
8) Allow to dry (or almost dry) and spot .3 ul alpha matrix onto each spot.
9) Keep plate in dark until processing.

